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1. Summary
Optogenetic depolarization of cells using the non-selective cation channel Channelrhodopsin-2 
(ChR2) provides distinct advantages over electrical stimulation. Using light as stimulus enables 
precise control over the membrane potential of cells within a specific area of intact organs. 
Furthermore, the selective overexpression of light-gated proteins allows cell type-specific and 
pain-free stimulation which could be of great benefit for future scientific and therapeutic 
approaches. 
In my thesis, I explored two potential applications of optogenetic methods in striated muscle: 
optogenetic defibrillation to terminate ventricular arrhythmia in intact mouse hearts and direct 
optogenetic stimulation of skeletal muscles. These new approaches could lead in the future to 
the development of optogenetic defibrillators and laryngeal pacemakers. Most experiments 
were performed with explanted hearts, isolated skeletal fibers and muscles or larynges from 
transgenic ChR2 expressing mice. To add translational perspectives, we also explored 
optogenetic defibrillation and intralaryngeal muscles stimulation after ChR2 gene transfer to 
wild type mice using adeno-associated virus (AAV).  
To investigate defibrillation in explanted mouse hearts, I initially developed a new protocol to 
enable induction of sustained ventricular arrhythmia using lower extracellular K+ concentration 
as well as adding the KATP channel opener Pinazidil and electrical burst stimulation. 
Optogenetic defibrillation by epicardial illumination was highly efficient in terminating 
ventricular arrhythmia in transgenic hearts with an average success rate of 97% when 
illuminating the whole anterior surface of both ventricles. The success rate of optogenetic 
defibrillation was depending on the pulse duration, the size of illumination and the light 
intensity. Importantly, we were also able to terminate ventricular arrhythmia in non-transgenic 
hearts even one year after AAV mediated gene transfer. The potential applicability of 
optogenetic defibrillation in the human heart was assessed in experimentally-calibrated 
computer simulations of a patient’s heart with infarct-related ventricular tachycardia. 
Interestingly, these simulations suggested that the epicardial illumination only terminated the 
arrhythmia when myocytes at all myocardial depths were sufficiently depolarized to block the 
wave front propagation. This is in line with the required high light intensities for successful 
optogenetic defibrillation in the experiments because lower light intensities would only 
depolarize cells in the epicardial layer. Because optogenetic stimulation would be in principle 
pain-free in patients, the proof for its feasibility could lay the foundation for the development 
of a new treatment option for patients at high risk for ventricular arrhythmia. Furthermore our 
results propose that optogenetic defibrillation is a new tool to investigate the mechanism 
- 1 -
underlying electrical defibrillation and could thereby help to improve current treatment 
strategies. 
Direct optogenetic stimulation of skeletal muscle was first proven in isolated Flexor digitorum 
brevis fibers and in intact soleus muscles, which could both be stimulated using brief light 
pulses. I used isometric force measurements and sharp electrode recordings for in depth 
biophysical characterization and quantification of force development. The force of light-
induced single twitches could be precisely controlled by varying the pulse duration and light 
intensity. During prolonged illumination (>1s), force declined to the basal level indicating the 
requirement of short repolarizations for the generation of tetanic contractions by the summation 
of Ca2+ transients. Thus we explored pulsed illumination using various repetition rates to induce 
maximum tetanic force. Optogenetic stimulation was most efficient with 10 ms long pulses at 
a repetition rate of 40 Hz reaching ~84% of the maximum force generated by electrical 
stimulation with 100 Hz. Increasing  repetition rate of light pulses over 50 Hz resulted in weaker 
force because the used ChR2-H134R variant has rather slow off kinetics (~20ms). In line with 
this, we showed that light pulse rates above 50 Hz lead to continuous depolarization of muscle 
fibers.  
Recurrent nerve paralysis is a severe complication of neck surgery, malignant processes or 
central neurological diseases and results in a fixed paramedian position of the vocal cords as 
well as life-threatening dyspnea in the case of bilateral paralysis. Current treatment options 
consist only of destructive surgery. Unfortunately the use of local electrical stimulation to 
restore laryngeal function faces severe technical limitations. Therefore I sought to explore direct 
optogenetic stimulation of intralaryngeal muscles in explanted larynges from ChR2 transgenic 
mice. Specific illumination of the individual intralaryngeal muscle groups led to an opening or 
closing of the vocal cords depending on the site of illumination. This proves the sufficient 
spatial resolution of light for selective stimulation of the intralaryngeal muscles groups. In 
addition, we were able to induce opening of the vocal cords in wild type mice after AAV-based 
gene transfer of ChR2 with light. Thus optogenetic stimulation could become a new treatment 
option for patients suffering from bilateral laryngeal paralysis. 
In conclusion, optogenetic stimulation can overcome the severe limitations of electrical 
stimulation of the heart and skeletal muscles. The new technologies, I have developed and 
characterized in this thesis, allow for the design of completely new stimulation patterns to 
address open questions in muscle physiology. Furthermore, optogenetic stimulation of striated 
muscles could become a new treatment option for patients enabling selective and pain-free 
stimulation with few side effects.  
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2. Introduction 
2.1 Excitability of muscle cells 
Every eukaryotic cell has a membrane consisting of a lipid bilayer which separates and 
electrically isolates the cytosol from the extracellular space. Charged ions are thereby unequally 
distributed between the intracellular and extracellular compartment leading to the formation of 
electrochemical gradients across the cell membrane for each type of ion. Ions can only cross 
the membrane by active transport or passive conductance through ion channels. Ion channels 
are proteins within the membrane which form a pore, selective for specific kinds of ions and 
allow them to cross the membrane along their electrochemical gradient. Therefore, expression 
of the different types of ion channels, their open probability and single channel conductance 
determines the membrane potential. Every cell type has its characteristic expression pattern of 
ion channels and transporters. Normally, the membrane potential is determined by K+ and Cl- 
channels and is therefore negative (Figure 1). In addition, the opening and closing of ion 
channels can be under control of distinct physical or chemical stimuli leading to change in the 
current flow through the membrane and thereby the membrane potential over time.  
 
Figure 1: Schematic drawing of a cell and its 
membrane consisting of a lipid bilayer (yellow) 
which is impermeable for charged ions. Unequal 
distribution of ions between the intra- cellular 
(grey) and the extracellular compartment results 
in an electrochemical gradient across the 
membrane. The permeability of the membrane 
for each ion is depending on which ion channels 
are open and determines the membrane 
potential. At rest, the conductance is the highest 
for K+ and Cl- ions resulting in a negative membrane potential. 
 
Neurons and muscle cells are excitable cells, which describes that they can be activated by an 
external stimulus. This results in a stereotypic sequence of opening and closing of distinct ion 
channels leading to a rapid change of the membrane potential, known as the action potential 
(AP). In skeletal and heart muscle cells, the excitation by APs triggers a series of intracellular 
events which eventually result in the contraction of cells, a process known as excitation-
contraction-coupling.1 Although the overall principle of this mechanism is similar in skeletal 
and heart muscle cells, the individual steps show variations in both cell types. Therefore I will 
describe the exact mechanism within both cell types separately in the next paragraphs. 
Ventricular cardiomyocytes are normally inactive because of a very stable resting membrane 
potential which is maintained almost exclusively by the so-called inward rectifying K+ currents 
(IK1) through Kir2.1 channels. Therefore the resting membrane potential is close to the Nernst 
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equilibrium for K+ at approximately −80 to −90 mV. To evoke an AP, ventricular 
cardiomyocytes normally require electrical activation from surrounding myocytes which are 
intercellularly coupled through ion conducting gap junctions. If a propagating excitable wave 
front arrives at a cardiomyocyte, the membrane potential becomes depolarized by current flow 
from the adjacent already depolarized cardiomyocytes until the AP threshold is reached. This 
initiates the AP (phase 0) with a very fast depolarization above +30 mV because of opening of 
voltage-gated Nav1.5 Na+ channels. The AP threshold is therefore depending on the availability 
and the membrane potential required for opening the Na+ channels and once they are activated, 
an AP with its stereotypic series of ion channel opening and closing is running automatically 
without requiring any further external input (Figure 2A and B): Within very few milliseconds 
(1-5ms), the Na+ channels inactivate and transient outward Kv4 channels open briefly, leading 
to outward Ito current and a partial repolarization in phase 1 (Figure 2A and C). This is followed 
by phase 2 with the characteristic AP plateau sustained by inward Ca2+ currents through L-type 
Ca2+ channels (Cav1.2) (Figure 2A and B). The flow of Ca2+ ions increases the local Ca2+ 
concentration in a small intracellular space between the external cell membrane (the 
sarcolemma) and the internal membrane of intracellular Ca2+ stores, the sarcoplasmic reticulum. 
This triggers the opening of Ryanodine receptors type 2 and a large release of Ca2+ from the 
sarcoplasmic reticulum, a mechanism termed Ca2+-induced-Ca2+-release.1 All together these 
events rise the intracellular Ca2+ concentration, a so called Ca2+ transient (Figure 2A), which 
initiates contraction of the cell. At the end of the AP (phase 4), Ca2+ channels close and the 
repolarizing K+ hERG (IKr) channels and KvLQT (IKs) channels open leading to the return to 
the resting membrane potential and reactivation of IK1(Figure 2A and C).2,3 
The comparably long AP duration in cardiomyocytes (300-400 ms) resulting from the Ca2+ 
currents during phase 2 and the biophysical gating mechanism of Nav1.5 prevent a fast 
reactivation of the Na+ channels because they are in an inactivated state until the membrane 
potential is repolarized below −50 mV. The time period during which myocytes cannot be 
activated because of this mechanism is called refractory period and ensures the rhythmic and 
concerted electrical activity of the heart important for sufficient cardiac output. 
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Figure 2: The cardiac AP and the 
underlying ion currents in a 
ventricular cardiomyocyte. (A) 
Overlay of the typical AP shape 
(black) with the AP phases marked 
in red and the corresponding 
intracellular Ca2+ transient (blue). 
(B) Corresponding timing of Na+ 
(red) and Ca2+ (blue) inward 
currents during the cardiac AP. 
Note the sequential occurrence 
highlighted in the insert. (C) 
Overlay of the repolarizing K+ 
outward currents Ito (purple), IKr 
(brown), IKs (black) and IK1 (green) 
during the different phases of the 
cardiac AP (corresponding to A). 
Figure has been modified from 
Bartos DC et al., Comprehensive 
Physiology 2015.3 MP: membrane 
potential; I: current density. 
 
 
 
 
In contrast to the electrically well-coupled cardiomyocytes, skeletal muscle fibers do not 
express gap junctions and are electrically isolated from each other. This allows them to be 
individually activated by their respective motor neurons. In addition, each skeletal muscle is 
comprised of different types of muscle fibers. The slower contracting type generates less force 
but is also less prone to fatigue development during continues activation. This is why the slow 
muscle fiber types are normally activated first, especially when steady contraction over 
prolonged time period is desired. In contrast, faster muscle fiber types can generate more force 
but only during shorter time periods and become therefore activated only if high force 
generation for short time periods is required. For skeletal muscle contraction, an AP must be 
evoked in a motor neuron and propagated along the axon to the presynaptic end where it results 
in an opening of neuronal Ca2+ channels. The elevated Ca2+ concentration in the presynaptic 
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terminal is leading to exocytosis of vesicles containing the neurotransmitter acetylcholine. 
Within the neuromuscular junction, acetylcholine activates nicotinic acetylcholine receptors at 
the postsynaptic side, which is the so called motor endplate of the skeletal muscle fiber. This 
results in opening of the non-selective nicotinic acetylcholine receptors leading to Na+ inflow 
and little depolarization. Subsequently an AP starts by activation of large and fast Na+ currents 
through Nav1.4 channels. To ensure that every neuronal stimulus successfully triggers an AP, 
the Nav1.4 channel density is 3-7 times higher around the motor endplate implying lower 
excitability at the other parts of the muscle fiber. Depolarization subsequently activates the 
skeletal isotype of L-type Ca2+ channels (Cav1.1) which act primarily as voltage sensors and 
directly activate Ca2+ release via ryanodine receptors type 1 from the sarcoplasmic reticulum 
leading to a rise in Ca2+ concentration and contraction.  Because the skeletal  L-type Ca2+ 
channels do not contribute significantly to the AP shape,4 the skeletal muscle fibers repolarize 
very quickly within 1-4 ms after the AP onset. The fast repolarization is due to the fast 
inactivation of the Na+ channels and supported by repolarizing K+ and Cl- currents.5 For the K+ 
currents, a slow and fast type of voltage activated delayed outward K+ channels has been 
described in slow fibers whereas only the fast channel type is present in fast fibers in rats.6 In 
contrast to cardiomyocytes, the resting membrane potential of skeletal muscle fibers is 70% due 
to conductance of Cl- ions and only 30% is attributed to K+ currents.5,7 Due to the fast 
repolarization of the AP, the refractory period for re-excitation is much shorter than the duration 
of the Ca2+ transients. Thus a closely timed second stimulus can evoke a second AP leading to 
the summation of Ca2+ release events. This results in increased force generation during so called 
tetanic contractions of skeletal muscles,4 a feature which is not present in the heart muscle.  
Taking together, ventricular cardiomyocytes and skeletal muscle fibers are normally inactive 
unless they are electrically excited by surrounding cardiomyocytes or neuronal input, 
respectively. Once the voltage threshold for Na+ channel activation is reached, a free-running 
AP triggers cytosolic Ca2+ increase and thereby contraction. Despite an overall similar 
principle, details within the excitation-contraction coupling machinery are different between 
both cell types with a profound impact on their electrical excitability. 
 
2.2. Electrical stimulation 
The first description of electrical stimulation of muscle cells was made in the 18th century by 
Luigi Galvani. In his opus “De viribus electricitatis in motu musculari”, he reported that the 
muscles of frogs’ legs start contracting when they were getting in touch with an electrical spark. 
Not only did these observations lead to the development of electrical stimulation of muscles 
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per se, they also laid the foundation for the whole field of electrophysiology and 
electrochemistry.8 Electrical stimulation of excitable cells can be performed in two ways: either 
a current is injected directly into the cytosol of one cell via an intracellular electrode or an 
extracellular electrical field is generated by two electrodes placed outside of the cells or the 
tissue. Both methods rely on sufficient depolarization above the threshold to evoke a free-
running AP. However, there are important technical and mechanistic differences which are 
described in detail in this chapter. 
 
2.2.1 Intracellular stimulation  
Intracellular stimulation relies on the patch clamp technique and requires the access of the patch 
pipette to the cytosolic part of the cell. Glass pipettes with a silver electrode inside and very 
small openings (typically 1-3 mm diameter) are brought adjacently to the cell membrane in 
order to establish a tight seal with G resistance between the membrane and edge of the pipette. 
By applying negative pressure, the cell membrane is disrupted within the pipette opening. The 
cytosol is now directly connected to the pipette solution in the so-called whole-cell-mode and 
is thus electrically coupled to the pipette electrode with a series resistance in the range of 10 
M. This allows measuring the membrane potential in the current clamp mode and its tight 
control by current injection into the cytosol.9 
Unfortunately getting access to the cell is technically challenging, requires one electrode per 
cell and is typically limited to a maximum of two cells which can be investigated and stimulated 
simultaneously. In addition, the pipettes are made of glass which complicates its use in 
contracting single muscle cells and in moving organs such as the beating heart or contracting 
skeletal muscles. In excitable cells, the injected current charges the membrane uniformly 
leading to depolarization until the threshold of Na+ channels for generation of a free-running 
AP is reached. Because of the relatively high membrane resistance, the amount of current 
required to excite isolated muscle cells is considerably low and the current injection to evoke 
APs in single cells is rather unproblematic. Importantly, this approach allows in principle 
precise control of the membrane potential of the whole cell without spatial differences (Figure 
3). Measuring simultaneously the membrane potential enables feedback control and allows 
keeping the cells at a chosen membrane potential throughout the whole cell (voltage clamp 
mode) with minor risk of so-called loss-of-voltage-control, at least in small cells.10  
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Figure 3: Intracellular electrical stimulation of 
a cell. To get access to the intracellular 
compartment, the patch pipette is attached to 
the cell surface and the membrane within the 
opening of the pipette is disrupted. Thereby the 
cytosol is directly connected to the electrode 
allowing homogenous voltage control by 
current injection.   
 
In contrast, a spatially uniform control over the membrane potential is not possible in larger 
cells or electrically coupled syncytium of cells such as the much longer adult skeletal muscle 
fibers11 or the well-coupled cardiomyocytes in the intact heart, respectively. Because of the hole 
in the cell membrane and the relative large solution volume in the patch pipette, the intracellular 
fluid is rapidly dialyzed. While this effect can be utilized to adjust the concentration of some 
intracellular compounds, it also leads inevitably to wash out of many important cytosolic 
components resulting in a “run down” of channel activity and limitation of the experiment time 
to several minutes.12 In conclusion, intracellular electrical stimulation can be used to trigger 
APs in excitable cells and allows fine-grain and sustained control of the membrane potential 
but requires the use of electrodes affecting the cytosol and is restricted to isolated single cells.  
 
2.2.2 Electrical field stimulation of single cells 
Extracellular field stimulation of single muscle cells can be performed using two electrodes in 
the extracellular solution surrounding the cells. Within the electrical circuit, the electrodes and 
the extracellular solution have different electrical behavior. The electrodes carry the current by 
electron transfer and the solution carries charge by ion movement. Because of this physical 
difference, current injection into the electrical circuit leads to building of an interphase between 
the electrodes and the external solution to enable transfer of the charges to close the electrical 
circuit. This charge transfer between electrodes and solution can happen by two different 
mechanisms in dependence of the amount of electrical energy fed into the circuit. If the current 
injection is small and short, the current passes through the solution by redistributing charged 
ions within the fluid without real electron transfer from the electrode to the solution. This 
process is called the non-faradic or capacitive reaction because the interphase between the 
electrode and the solution can be regarded as capacitator. Importantly, this process is fully 
reversible and considered to be harmless. Above a certain threshold, electrons are exchanged 
between the ions within the solution and the electrodes by chemical reactions. This second 
mechanism is called faradaic reaction consisting of redox processes which are predominantly 
non-reversible. Unfortunately, the resulting end-products like reactive oxygen species, O2, Cl2 
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and H2 diffuse away from the electrode and can be toxic to the cells.13 Therefore the duration 
of electrical pulses is limited to the millisecond range (3-5 ms maximum), and also pulsed 
stimulation of cells over prolonged time periods is technically very challenging because it 
requires constant exchange of the extracellular fluids to wash out the toxic reagents. 
At a certain distance from the electrodes and the interphases, the so called far-field, the energy 
of the electrical field is the same and influences the cells indirectly due to the redistribution of 
ionic charges on the extracellular side. Because positively charged ions (cations) are attracted 
towards the negatively charged electrode, this electrode is termed cathode and the positively 
charged electrode is the anode (Figure 4, symbols on the electrodes). Within the electric far 
field, each cell is exposed to the different poles of the electrical field, which results in a variation 
of the external potential parallel to the orientation of the electrical field (Figure 4, symbols 
outside the cell). As a result, the intracellular parts of the cell near the cathode (Figure 4, green) 
are relatively depolarized and the parts facing the anode become relatively hyperpolarized 
(Figure 4, red). The extracellular redistribution of charges activates different voltage-dependent 
ion channels in the distinct parts and in excitable cells an AP is evoked once the whole cell is 
depolarized above the AP threshold.14 Importantly and in clear contrast to intracellular 
stimulation, extracellular field stimulation is not able to hold the membrane potential at a chosen 
level. Furthermore, the electrical stimulation is severely affecting parallel electrical recordings 
by inducing large artefacts.15  
Figure 4: Electrical field stimulation of a single cell. Within the electrical far field from the electrode, 
distribution of the charged ions is changed leading to depolarization at the end facing the cathode (-) 
and hyperpolarization at the site next to the anode (+). 
In sum, extracellular field stimulation can be used to trigger AP in excitable cells but cannot be 
used to clamp the cells at a certain membrane potential. It also co-induces hyperpolarization in 
some parts of the cells, results in stimulation artefacts in electrical recordings and can lead to 
the production of toxic reactions. 
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2.2.3 Electrical field stimulation of muscle tissue 
Electrical field stimulation of muscle tissue has to be considered quite differently compared to 
stimulation of single muscle cells. The intracellular compartment and the extracellular solution 
are highly anisotropic due to varying ion channel expression in different parts of the membrane, 
intracellular resistances and the complex architecture of muscle tissue, respectively. Therefore, 
electrical field stimulation always induces simultaneously depolarization, called the virtual 
cathode, and hyperpolarization, called the virtual anode around the stimulating cathode placed 
within or next to the muscle tissue. The size and amplitude of the effects of the electrical field 
stimulation are not only determined by the physical features of the stimulus amplitude but also 
by the structural architecture and electrophysiological behavior of the tissue. Because these are 
both very different for myocardium and skeletal muscle, the electrical field stimulation will be 
separately described. 
 
2.2.3.1 Electrical stimulation of the heart 
The myocardium has a very distinct structure with varying orientations of cell bundles adjacent 
to each other.16,17 Within these bundles, each cardiomyocyte has a rectangular shape and is 
approximately 200 µm long with a diameter of 20 µm. The cytosolic parts of the 
cardiomyocytes are coupled electrically to each other by gap junctions. Thus the whole heart 
can be considered as an electrical syncytium of single cells. Therefore for electrical pacing of 
the heart, it would be in principle sufficient to trigger an AP in one cardiomyocyte and the rest 
of the myocardium will be activated in an avalanche-type of cell-to-cell excitation. However, 
more electrical energy is required to depolarize one cardiomyocyte within an electrical 
syncytium of cells towards the AP threshold. This is because the induced current (source) in 
one cardiomyocyte will be distributed through gap junctions to all adjacent cells which are all 
adding repolarizing IK1 currents, counteracting the depolarization and can be considered as sink. 
This principle is called sink-source relationship and explains why much more inward current is 
required to depolarize one well-coupled cardiomyocyte within the heart compared to an isolated 
single cardiomyocytes.  
Importantly, the amount and localization of de- and hyperpolarization and their expansion 
within myocardial tissue cannot be controlled using electrical stimulation due to the specific 
anatomical and physical features: Because gap junctions have higher resistance than the cytosol 
of cells, they lead to an additional resistance within the intracellular compartment which is not 
present in the extracellular space. Furthermore, the intercellular resistance between 
cardiomyocytes is crucially determined by the amount of gap junctions formed between the 
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cells. Gap junctions are most prominent at the intercalated disks at the short end of the 
cardiomyocytes which results in better electrical coupling in the longitudinal than the 
transversal direction of fiber orientation.18 This intercellular anisotropy within the intracellular 
compartment is causing the effect within myocardial tissue that depolarization expands more in 
the transversal than the longitudinal direction of the muscle fiber orientation19 resulting in a dog 
bone shape of the virtual cathode.20 The virtual anode is the hyperpolarized tissue which is 
simultaneously induced perpendicular to the virtual cathode and parallel to the fiber 
orientation.21 Furthermore within the extracellular compartment, blood vessels, endocardial 
structures such as trabeculae and papillary muscles, extracellular cleft spaces as well as varying 
fiber orientations are adding up to structural inhomogeneity which has a great influence on the 
electrotonic coupling between the cardiomyocytes. All these effects are causing a high regional 
variability and inhomogeneity in the electrical sink, which is why the regional anatomy has a 
significant impact on excitability, refractoriness and thus ability to successfully capture a local 
electrical stimulus.22  
In conclusion, electrical field stimulation of myocardial tissue simultaneously triggers 
depolarization as well as hyperpolarization around the stimulating electrode. Unfortunately it 
is almost impossible to control and predict the extent of these virtual electrodes in the electrical 
syncytium of the heart due to the anisotropic electrical conductivity as well as the structural 
heterogeneity of the myocardium. 
 
2.2.3.2 Electrical stimulation of skeletal muscles 
In contrast to the myocardium, skeletal muscles consist of muscle fibers up to several 
centimeters long oriented parallel to the macroscopic muscle and in the direction of force 
generation. Importantly all myofibers are electrically isolated from each other while this allows 
fine-grain control of the generated muscle force because individual motoric units can be 
separately activated, all muscle fibers have to be individually stimulated to induce maximum 
force. The excitability of the skeletal myofiber varies between the fiber types and along the 
membrane.5 Because each fiber is not spanning from end to end of the whole muscle, all fibers 
together have to form a complex structure including nerves, vessels and connective tissue.23 
This structural architecture explains why direct electrical stimulation of the whole skeletal 
muscles requires high energy24-26 to efficiently excite all fibers at the different loci within the 
muscle. This need for high electrical energy leads to co-stimulation of adjacent muscles and 
nerves as well as generation of toxic gases.13 In addition, both slow and fast muscle fibers are 
activated equally without the above mentioned important physiological recruitment patterns.  
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Skeletal muscles can also be activated by indirect electrical stimulation either of the innervating 
motoric nerve outside the muscle or of the presynaptic nerve endings of the neuromuscular 
endplate within the muscles. Importantly, such indirect nerval stimulation requires over 200 
times less energy25 and thus has far fewer side-effects compared to the direct electrical 
stimulation of the muscle fibers. However, co-activation of other neurons in the vicinity leads 
to simultaneous stimulation of other muscles as well as many other neurogenic effects. In 
addition, the electrically stimulated motor neurons are non-selectively activated recruiting 
simultaneously the fast and slow muscle fibers which is also in contrast to the physiological 
recruitment and leads to increased fatigue development during prolonged stimulation 
periods.27,28 Furthermore, the indirect stimulation requires intact motoric nerves and unaltered 
AP generation and propagation within the neuron as well as functional signal transmission at 
the neuromuscular endplate. Therefore indirect electrical stimulation of skeletal muscle is 
limited to the all-or-nothing principle of single AP propagation and quantal synaptic 
transmission and thus does not allow continuous or subthreshold stimulation of the muscle fiber 
itself.  
Taken together, the direct electrical stimulation requires very high energy and is thus practically 
unusable in intact muscles. Indirect electrical stimulation via the innervating nerves can be used 
to excite skeletal muscles with much less electrical energy but requires intact neuronal function, 
provides only low spatial resolution and allows only generation of short AP in the muscle fiber. 
  
2.2.4 Electrical stimulation in patients 
Since the first implantation in the 1950s,29 cardiac pacemaker became the most successful 
application of electrical stimulation in clinical routine. Subsequently, it was detected that higher 
electrical energy can be used to terminate cardiac arrhythmia leading to the invention of 
cardioversion and defibrillation. Other possible applications of electrical stimulation such as 
laryngeal or gastric pacemaking have remained stagnant in early developmental stages for 
decades. All of these approaches suffer from similar intrinsic technical problems using 
electrical stimulation but with varying impact on their applicability. 
Patients with bradycardia suffer from low beating rate of the heart leading to reduced cardiac 
output and insufficient blood and oxygen supply of the body, which can be a life-threatening 
condition. Cardiac pacemakers for electrical stimulation are currently the first option to treat 
bradycardia by electrical stimulation of the heart. Restoring normal heart rate by electrical 
stimulation has proven to be a safe and very efficient treatment.30 This is mainly because the 
electrical energy required to stimulate the heart is relatively low and does not induce sensation 
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or pain because the beating of the heart is not perceived by the patient under physiological 
conditions and the myocardium itself is relatively insensitive to pain except during ischemia.31 
Therefore cardiac pacemakers are well-tolerated by patients. The main risks of cardiac 
pacemakers arise from surgical implantation of the device and the requirement for electrical 
leads to be impaled into the myocardium causing infections. After the implantation, the battery 
lasts on average no longer than 10 years and the electrode leads can dislocate from the 
myocardium as well as fibrosis can form around the electrode reducing the efficiency of 
electrical stimulation.32 All these complications require an invasive correction or re-
implantation with the additional risk for infections.  
Ventricular tachycardia and fibrillation are arrhythmic states of the ventricles characterized by 
rapid regional excitation of the cardiomyocytes leading to uncoordinated and ineffective 
beating and thus a complete loss of cardiac output. This results in an acute drop in arterial blood 
pressure, syncope and eventually sudden cardiac death. The only primary therapy for these 
acutely life-threatening arrhythmias is electrical defibrillation with the aim to reestablish the 
normal heart rhythm.33 Unfortunately, the electrical energy required for defibrillation to 
terminate ventricular arrhythmia is several orders of magnitude higher than for electrical 
pacing. This is because electrical pacing relies on stimulating one small area of the myocardium 
with intrinsic conduction of electrical activity through gap junctions to the remaining heart but 
defibrillation requires the synchronous depolarization of a large mass of ventricular tissue.34 
Therefore the term electrical shock for defibrillation was introduced as the required high energy 
leads to many undesired side effects, in particular massive co-excitation of nerves and skeletal 
muscles and severe pain.35 
Besides the use of external defibrillators during acute cardiopulmonary resuscitation, patients 
with a predictable high risk to develop ventricular arrhythmia can be treated with implantable 
cardioverter/defibrillators (ICD).33 These devices monitor online the electrical activity of the 
heart and apply high energy electrical shocks with implanted electrodes once a tachyarrhythmia 
is detected. To apply the high energy shock, ICD must charge internal capacitators which 
requires several seconds.36 Therefore most patients with severe ventricular arrhythmia are 
already unconscious during the electrical shock and are thus not aware of the massive pain. 
However, arrhythmia detection algorithms have to be made very sensitive to assure that every 
ventricular arrhythmia is detected. This implies the risk of unjustified application of electrical 
shocks in conscious patients because of false positive arrhythmia detection. In fact, such 
inappropriate shocks have been reported to constitute one third of all shocks and more than 10% 
of ICD patients have encountered the very traumatic experience of an inappropriate shock.37 
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For this reason, implantation of cardiac defibrillators is associated with a high risk for anxiety 
and depressive disorders as well as post-traumatic stress syndrome.38 Furthermore, electrical 
shocks are so strong that they can physically damage the myocardium39 and it has been shown 
that there is a drop in contractility and cardiac output after electrical shocks.40 For these various 
reasons detailed statistical analysis revealed that despite being acutely live-saving, applying 
electrical shocks is associated with an increased mortality over long term.41 Taken together, 
electrical stimulation of the heart is used in clinical routine and electrical pacemakers are safe 
and efficient in treating bradycardia. Electrical shocks for defibrillation are acutely life-saving 
but the required high electrical energy induces massive pain, damages the heart and is 
associated with increased mortality. 
Direct electrical stimulation of skeletal muscles is not accepted by patients due to the 
unavoidable induction of massive firing in sensible and pain neurons and many other side 
effects.25 Indirect electrical stimulation through the motoric nerve requires less power25 and can 
be thus much better tolerated. Hence, indirect electrical stimulation has been suggested to 
restore skeletal muscle function after spinal cord injuries42 and to improve training and to 
restrengthen muscles in injured patients.43,44 Recent publications have shown the benefit of 
electrical stimulation of the hypoglossal nerve to prevent relaxation of the tongue and 
subsequent closure of the airway in patients suffering from obstructive sleep apnea.45  
Similarly, electrical stimulation of the phrenic nerve was tested in patients to restore normal 
ventilation by diaphragm contraction46 which could improve outcomes during long term 
mechanic ventilation in comatose patients or after lung transplantation. However, the indirect 
electrical stimulation of the innervating nerve in distance to the muscle itself is restricted to 
motor nerves which innervate only one muscle. In other anatomical situations, all other muscles 
innervated by the same nerve would be co-stimulated which is in contrast to the physiological 
concerted movement of hands or legs and is an absolute requirement for normal behavior. In 
addition, indirect stimulation cannot be performed in diseases affecting the motor nerve or the 
neuromuscular junction, such as amyotrophic lateral sclerosis or myasthenia gravis.   
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2.3 Optogenetic stimulation 
2.3.1 History of optogenetic tool development 
Optogenetics is a new technique consisting of genetic modification of a certain cell type of 
interest in order to control the membrane potential, intracellular signaling or other cellular 
processes with light. This approach provides several significant advantages over traditional 
electrical or pharmacological strategies: Genetic targeting allows expression of light-sensitive 
proteins only in a specific cell type of interest and thereby only these cells will be directly 
influenced by the illumination. Cell type-specific stimulation was identified by neuroscientists 
to be of special interest because it enables the stimulation of a specific subset of neurons to 
determine their respective function within the intact brain. Furthermore light can be focused on 
a certain region with high precision and fine-grain control of intensity. These two advantages 
were first shown by the group of Gero Miesenböck in 2002, who demonstrated that genetic 
expression of a three-gene Drosophila phototransduction cascade in neurons allowed the 
control of neuronal activity by illumination.47 However, this system required three proteins to 
be overexpressed and suffered from rather low temporal kinetics because of the involvement of 
a slow G protein signaling cascade. Therefore, the search continued for a light-gated ion channel 
which would provide greater temporal resolution depending solely on the channel gating 
kinetics.  
Since the 19th century, it was known that algae like Chlamydomonas reinhardtii were light 
sensitive.48 Upon illumination with low light intensity, the cells swim towards the light source 
whereas higher light intensities trigger escape reactions. Because it was found much later that 
illumination with light evoked this behavior within very few milliseconds, it was proposed that 
photon energy would directly interact with an ion channel.49 Thus light sensitive proteins were 
searched encoded within the genome of algae. This genomic search was facilitated by the 
knowledge gathered from the discovery50 and detailed investigations51,52 of the light-inducible 
proton pump bacteriorhodopsin since the 1970s, which allowed to search for sequence 
homologies within the genome. Importantly, overexpressing bacteriorhodopsins, as well as the 
Cl- transporting pump 19urgeries19sin in oocytes of Xenopus laevi was established for their 
detailed electrophysiological characterization from the 1990s on.53,54 This method became very 
useful when Peter Hegemann and his group discovered two new gene sequences for large 
microbial-type rhodopsins in a cDNA library from Chlamydomonas reinhardtii in the early 
2000s because it immediately enabled the proof by Georg Nagel and Ernst Bamberg that these 
two genes encoded in fact light-gated ion channels.55,56 The first gene encoded for a proton 
channel but the second gene encoded for a light sensitive non-selective cation channel, which 
- 15 -
was called Channelrhodopsin-2 (ChR2). ChR2 consists of seven transmembrane helices, binds 
covalently retinal as chromophore and changes it conformation upon illumination with blue 
light opening its pore. Under physiological conditions in mammalian cells, ChR2 is 
predominantly permeable for monovalent cations, which leads to inward currents and 
depolarizes the cell membrane. Because of its fast on- and off kinetics of few milliseconds, 
ChR2 seemed to be well-suited for optogenetic approaches. This was also due to its simplicity 
consisting of only 315 amino acid and requiring only all-trans retinal as co-factor which is cheap 
and easy to add in in vitro experiments and already present in most mammalian tissue in vivo.57 
In addition, there is no constitutive activity without illumination such that no ChR2 current is 
present in the dark. Finally ChR2 overexpression is well tolerated in all tested cell systems. For 
these reasons, the first optogenetic applications were reported shortly after the discovery of 
ChR2 independently by five different groups. The group of Karl Deisseroth and Hirumo Yawo 
proved the high temporal precision by demonstrating the feasibility to evoke APs by simple 
LED flashes in neurons ex vivo in a light pulse-to-AP manner.58,59 The first in vivo applications 
were shown by Stefan Herlitze and his group controlling the burst activity of neurons within 
the spinal cord of chicken embryos60 as well as by the group of Georg Nagel and Alexander 
Gottschalk by light-induced contractions in the muscles of Caenorhabditis elegans 
nematodes.61 Almost at the same time, the group of Zhou-Hua Pan demonstrated that inscribing 
light sensitivity by ChR2 expression in surviving inner retinal neurons of blind mice can be 
used to restore the ability to react to light.62 This pioneering work established the idea that 
optogenetic stimulation could also be eventually used for therapeutic approaches (see chapter  
2.3.4). Ever since, optogenetic stimulation has gained increasing importance especially in the 
field of neuroscience allowing for the first time the analysis of connections between specific 
subtypes of neurons and brain regions as well as the investigation of the specific neuronal 
causes for whole animal behavior in vivo. 
Besides light-induced depolarization via ChR2, the optogenetic toolbox was soon expanded. 
Light-inducible H+ and Cl- pumps from bacteria and fungi enabled the export of positive H+ 
ions or the import of negative Cl- ions, respectively. This can be used for light-induced 
membrane hyperpolarization to inhibit electrical activation.63,64 However, their transport rate is 
rather low and they require ~10 times higher light intensities compared to ChR2 for full 
activation. Recently, Cl- selective ChR2 variants65,66 have been developed by amino acid 
exchange and novel natural anion conducting light gated channels have been discovered.67 
Their ability to silence electrical activity in excitable cells depends strongly on the Nernst 
potential for Cl-  and  for example in cardiomyocytes with a relatively high intracellular Cl- 
- 16 -
concentration their activation leads to depolarization.68 In the recent years, many other 
optogenetic approaches have been developed which aim to make intracellular signaling 
cascades light-inducible. The spectrum ranges from light-switchable G protein coupled 
receptors,69-75 light inducible enzymes including adenylyl cyclases,76,77 guanylyl cyclases78-80 
and phosphodiesterases81 to light-inducible tools to modulate gene expression82 and induction 
of apoptosis.83  
Optogenetic stimulation has developed rapidly since its initial inception in the early 2000s 
thanks primarily to the concerted effort of the neuroscience research community. This can be 
explained by the enormous potential this new technique has to offer both for basic research as 
well as future clinical approaches. While a variety of different tools exist nowadays, ChR2 is 
still currently the best suited candidate for light-induced depolarization. Because of its distinct 
advantages and simplicity, optogenetics entered quickly the field of basic research and gathered 
special importance in the investigation of the brain and its function. 
 
2.3.2 The light-sensitive cation channel Channelrhodopsin-2  
The natural ChR2 protein is composed of seven transmembrane helices and an additional 
cytosolic C-terminal appendix which is not necessary for its channel function56 and therefore 
excluded for optogenetic approaches.84 Within the hydrophobic center of core protein, retinal 
is bound to helix 7 via a lysine with a Schiff base linkage.85,86  Absorption of blue light by 
retinal  with a peak at 485 nm leads to its isomerization from the all-trans to 11-cis state which 
triggers a conformational change of the whole protein including tilting of helix 2 and opening 
of an ion conducting pore (Figure 5A).87 
This signal transduction from photon absorption to ion conductance occurs very quickly with a 
rise time of the photocurrent as fast as 200 μs when using supramaximal illumination. During 
continuous illumination, the peak current declines quickly to a steady state88 current which 
persists unaltered during illumination.56 After termination of illumination, the ChR2 current 
deactivates with a decay constant (τoff) of approximately 10 ms (Figure 5B).64 The diameter of 
ion conducting pore is slightly larger than the pore in voltage gated Na+ channels allowing to 
pass monovalent cations depending on their size (H+ >> Gd+ > Li+ > Na+ > K+) and to a much 
lesser extent bivalent cations (Ca2+ > Sr2+ > Ba2+ ≫ Zn2+). Because of this non-selective 
monovalent cation conductance, ChR2 photocurrents reverse at physiological ion 
concentrations around 0 mV resulting in inward currents and depolarization at negative 
membrane potentials and in outward currents and hyperpolarization at positive membrane 
potentials (Figure 5C).56 The currents through ChR2 are therefore strongly dependent on the 
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membrane potential with a slight inward rectification. Although ChR2 currents within the 
whole cell are large in the range of several pA/pF, the single channel conductance is so small 
(<50 fS) that it cannot be directly measured and was estimated by noise analysis 
experiments.56,85,89 Thus, the fact that ChR2 leads to significant whole cell currents is mainly 
due to its massive and non-harmful expression level even in mammalian cells. 
 
Figure 5: Light-induced pore opening and currents in ChR2. (A) Picture of structure of ChR2 from a 
molecular dynamics simulation displaying the retinal binding and the probable ion conducting pore (blue 
arrows) opened by tilting of transmembrane domaine 2 (TMD2) after light-absorption and conformation 
change of the retinal. Picture is taken from K. Deisseroth and P. Hegemann, Science 2017.90 (B) 
Illumination with blue light (470 nm, 5 mW/mm2) induces inward currents at a negative membrane 
potential (−40 mV). Figure is adopted and modified from Lapp H. et al., Scientific Reports 2017. (C) 
Current (I) to voltage (MP: membrane potential) relationship of ChR2 H134R in a cardiomyocytes. Note 
the typical inward rectification. Figure is taken and modified from Bruegmann T. et al., Nature methods 
2010.91 
 
After the identification of the natural ChR2, many mutations were performed and other natural 
Channelrhodopsins (ChR) from different species were investigated to create new superior 
variants.64 The first mutant was generated by a single amino acid exchange from a Histidine to 
an Arginine at position 134 (ChR2 H134R), anticipated from prior experiments with 
bacteriorhodopsin. This gain-of-function mutation led to lesser desensitization and larger 
stationary photocurrents compared to wild type ChR2 but had a slightly slower deactivation 
kinetics (τoff ~ 20ms ).61 Interestingly, the ChR2 H134R variant is still the most commonly used 
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ChR variant because of its well defined expression within the membrane and the good 
biophysical properties.  
Many new ChR variants have been described with varying ion selectivity, gating kinetics, larger 
currents and distinct wavelength characteristics.64 CatCh was generated by a single point 
mutation (L132C) and was reported to have an enhanced Ca2+ permeability leading to more 
efficient depolarization at lower light intensities with faster kinetics.92 While CatCh was 
indirectly faster due to activation of K+ channels by the subsarcolemmal Ca2+ increase, other 
variants such as ChETA,93 ChIEF89 or Chronos94 showed biophysically faster off-kinetics of 
the photocurrent itself. Other approaches were undertaken to slow down the closing of ChR2 
in order to make the channel bi-stable. These so-called step-functional opsins can be activated 
by a short light pulse of one wavelength, stay open thereafter and can be inhibited by a short 
pulse of another, typically longer wavelength.95-97 In experiments in which continuous 
depolarization over long periods is required, such step-functional opsins allow for a large 
reduction of the required photons over time. Interestingly, comparing many ChR variants 
revealed that there is a strong correlation between the light sensitivity of the variant and its 
deactivation kinetics.64 In addition to ChR variants with altered gating kinetics, efforts were 
undertaken to change the wavelength specificity by single point mutations, generating chimeric 
proteins and analysis of natural ChR variants.96,98-100 The most red-shifted ChRs are the 
ChRimson variant94 derived from the species Chlamydomonas noctigama and ReaChR99 which 
was created from different parts of Channelrhodopsin-1, ChR289 and ChR from Volvox cateri.88 
The advantage of this wavelength shift is that red light is less absorbed and therefore much less 
toxic and penetrates much deeper through biological tissue than blue light.101 In fact, the use of 
ReaChR allowed to trigger spiking within the motor cortex in awake mice with red light even 
through the intact skull.99 
Genetic modification as well as the discovery of new natural ChRs has led to a huge variety of 
light-gated channels which differ in their ion permeability, wavelength specificity, gating 
kinetics as well as their light sensitivity. While the H134R variant is still by far the most used 
ChR, other variants can be selected for specific purposes. However it has to be taken into 
account that good expression and toleration by the cells are the most important factors for 
optogenetic experiments.  
 
2.3.3 Light-induced depolarization of muscle cells 
Expressing ChR2 in cells allows depolarization by illumination. The great advantages of this 
approach are the possibility of cell-specific stimulation with precise spatial and temporal 
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resolution as well as fine-grain control over the extent of depolarization. Cell-specific 
stimulation can be obtained because only cells expressing ChR2 will be depolarized by light 
whereas non-expressing cells are usually not light sensitive. For this purpose, ChR2 must be 
expressed under the control of a promotor which is only active in the subtype of cells-of-
interest. This allows not only to decipher the exact role and function of the individual cell type 
within the whole organ or organism but also to prevent unwanted side effects of the light 
stimulation. Importantly, in contrast to electrical stimulation, co-excitation of nociceptive and 
pain neurons can be excluded if ChR2 is not expressed in these cells. Fortunately, ChR2 
stimulation does not require high light intensities which could lead to heat generation during 
continuous illumination.102,103  
The spatial resolution of the stimulation is defined by the ChR2 expression itself and the 
illumination. The ability to control the site of stimulation by ChR2 expression is of particular 
interest because ChR2 expression can also be restricted to distinct compartments or organelles 
within the cell104-106 to investigate the role of individual organelles or specific parts of the cell 
membrane. Without such targeted expression, ChR2 is equally distributed over the whole 
sarcolemma.91 Thus uniform illumination of the whole cell will result in homogenous 
depolarization over the whole cell (Figure 6A). Importantly, the amount of depolarization 
depends on the applied light intensity, the ion selectivity and inward rectification of ChR2 as 
well as the endogenous counterbalancing and repolarizing currents.  In tissue and organs, light 
can be precisely focused to defined regions of the surface. The actual depth of stimulation 
depends thereby on the light intensity and physical penetration of the light (Figure 6B). 
 
Figure 6: Light induced depolarization in ChR2 expressing cells. (A) Uniform illumination depolarizes 
the membrane homogenously which can be used to control the voltage without disturbing the cell 
membrane. (B) Illumination depolarizes all cells within the illuminated area primarily irrespective of the 
architecture of the tissue.  
 
The amount and location of cardiac tissue which will be depolarized by the illumination within 
an organ can be much better controlled than using electrical stimulation because optogenetic is 
primarily independent of the regional architecture of the tissue and does not induce virtual 
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anodes with hyperpolarized areas. The temporal precision of light-induced depolarization via 
ChR2 is determined predominantly by the on- and off-kinetics of ChR2 itself and to some part 
by the counterbalancing and repolarization ion currents of the cell under investigation. In clear 
contrast to electrical field stimulation, optogenetic depolarization can be used almost 
indefinitely because the steady state current of ChR2 is stable over seconds and minutes. 
Therefore optogenetic stimulation enables fine-grain control of the membrane potential without 
temporal limitations and high spatial resolution. Importantly, optogenetic stimulation enables 
to expand the possibilities of intracellular stimulation to the tissue level because of the 
advantageous physical properties of light. 
2.3.3.1 Optogenetic pacing of the heart 
While optogenetic stimulation very quickly entered the field of neurosciences, it took some 
years until its first applications could be demonstrated in cardiovascular research.107 In the first 
publication,91 we were able to show optogenetic stimulation of cardiomyocytes in vitro as well 
as the intact heart ex vivo and in vivo. In ChR2 expressing cardiomyocytes differentiated from 
transgenic murine embryonic stem cells or isolated from transgenic adult mouse hearts, light 
induced inward currents and evoked APs and contractions. Importantly, we proved that 
prolonged illumination can be used for sustained depolarization: At low light intensities, 
continuous illumination induced an acceleration of spontaneous beating in vitro, which we 
attributed to subthreshold depolarization in the pacemaking cells. High light intensities 
prolonged the AP resulting in a sustained depolarization at a membrane potential of 
approximately −30 mV (Figure 7A). Because this level of depolarization should be sufficient 
to keep Na+ and Ca2+ channels in the refractory state, we anticipated that optogenetic 
stimulation could be also used to block electrical activation in cardiomyocytes. This was proven 
by experiments with a spontaneously beating monolayer of cardiomyocytes in which localized 
illumination blocked the electrical activity selectively within the illuminated region (Figure 
7B). All together these findings were pointing towards the potential of optogenetic stimulation 
to terminate tachyarrhythmias.108 In addition to these in vitro experiments, we aimed to explore 
optogenetic stimulation in the intact heart and generated transgenic mice expressing ChR2 
H134R in ventricular and atrial cardiomyocytes. To enable high expression in muscle cells, we 
used the chicken-β-actin promotor. Importantly, we searched for unwanted side-effects by the 
ChR2 expression alone because a potential dark current or high expression within the 
membrane could alter the basic electrophysiological properties. However, we found no signs of 
cardiac hypertrophy or heart failure. Also ChR2 expression did not affect basic 
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electrophysiological parameters because the AP duration, resting membrane potential or the 
membrane resistance were not altered. 
 
Figure 7: Continuous illumination of cardiomyocytes. (A) Membrane potential recording from a ChR2 
expressing cardiomyocyte. Short illumination induced a free-running AP (left) whereas continuous 
illumination kept the cardiomyocytes depolarized. Grey dotted line indicates 0 mV. (B) Field potential 
recordings (cellular ecg) from two sites of a spontaneously beating monolayer of cardiomyocytes plated 
on a multi-electrode array: Prolonged illuminated of one region blocks the electrical activity selectively 
while the rest of the monolayer is unaffected and continues to beat spontaneously. Figure is adapted 
from Bruegmann T et al., Nature methods 2010.91  
 
To locally trigger supraventricular and ventricular extrasystolic beating, we used localized 
illumination of the atrium and ventricles of intact hearts, respectively. Interestingly, we were 
able reduce the illuminated area down to 0.05 mm2 for successful optogenetic pacing of the 
heart.91 These experiments laid out the tantalizing prospect that the spatial precision of 
optogenetic stimulation can be used to determine the number of cardiomyocytes which are 
required to generate extrasystolic beating within intact ventricles. This important question could 
only be addressed by computer simulations so far.109 Zaglia et al. expanded upon this idea by 
investigating the distinct requirements for the generation of extrasystolic beating within the 
conduction system compared to the working myocardium by using cardiomyocytes subtype 
specific ChR2 expression and varying illumination sizes.110 Almost at the same time of our 
initial publication, Arrenberg et al. reported successful optogenetic stimulation of the heart in 
embryonic zebra fish larvae.111 Besides optical pacing using ChR2, they employed the light-
inducible Cl- pump Halorhodopsin to inhibit electrical activity. In a series of elegant 
experiments, patterned illumination by a digital mirror device was used for precise spatial 
control of electrical inhibition to pinpoint the origin of the electrical automaticity during 
different developmental stages.  
After the initial reports expressing ChR2 directly in cardiomyocytes,91,111 another strategy was 
demonstrated in vitro using a cell-delivery technique. HEK293 cells expressing ChR2 were co-
cultured with wild-type neonatal rat cardiomyocytes. Because both cell types can electrically 
couple through gap junctions, the light-induced inward currents in the HEK293 cells can excite 
and pace the cardiomyocytes.112 This cell-cell coupling approach was further expanded using 
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fibroblasts expressing ChR2 or the light-gated H+ pump ArchT for pacing or electrical silencing 
of gap-junctional coupled wild-type cardiomyocytes.113 For optogenetic stimulation of hearts, 
the cell-delivery approach would have the advantage that only cell transplantation but no 
genetic modification of the myocardium is required. Computer simulations suggested that this 
approach might be suitable for optical pacing of a human heart.114 However, stable long term 
and effective cell engraftment of ChR2 expressing cells has never been proven and is highly 
questionable.115,116 Furthermore transplantation of non-excitable cells could lead to local 
fibrosis, electrical isolation and altered electrical properties of the host cardiomyocytes which 
is highly pro-arrhythmic in fibrotic heart tissue.117 
Viral gene transfer to express ChR2 directly within cardiomyocytes seems to be the better suited 
alternative for optogenetic stimulation of wild type hearts and maybe suited even for patients 
in the future. Viral transduction for cardiac optogenetics was first shown in vitro in adult guinea 
pig cardiomyocytes using adenovirus118 and in neonatal rat cardiomyocytes using lentivirus.119 
These experiments were used to construct and validate a computer model for ChR2 in 
cardiomyocytes118 and to terminate arrhythmia-like rotating spiral waves in a monolayer in vitro 
suggesting the potential use of optogenetics to treat cardiac arrhythmia.119 Unfortunately 
lentiviral transduction in humans can have detrimental side effects including malignant 
leukemia.120 In clear contrast, gene transfer using adenoassociated virus (AAV) has been 
demonstrated to generate high cardiomyocyte transduction rates with administrative safety in 
several clinical trials121,122 and the persistence of gene expression could be shown for more than 
2 years in the hearts of patients.123 Excitingly, several subtypes of AAV vectors were identified 
to have high tropism towards specific cell types enabling selective transduction with systemic 
injection.124 Among these, AAV encapsulated with proteins from the serotype 9 showed a 
strong tropism towards cardiomyocytes, at least in rodents.125 Therefore, we injected 
systemically AAV particles and observed robust ChR2 expression within the ventricles up to 
10 weeks after the injection (Figure 8A). This enabled reliable optical pacing in approximately 
75% of all hearts, both in vivo and in explanted hearts ex vivo (Figure 8B). By investigating 
hearts with different cardiomyocyte transduction rates, we were able to suggest that at least 
40% ChR2 expressing cardiomyocytes are required for optical pacing of the heart.126 This 
underlies the power of cardiac optogenetics to investigate electrical coupling between cells 
within the myocardium. In addition, the group of Lior Gepstein tested intramyocardial injection 
of AAV in rats and suggested that optical pacing from two distinct sites can be used to 
resynchronize the ventricular activity. Such an approach would be similar to current 
biventricular electrical pacing which is advantageous in heart failure patients with a bundle 
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branch block.127 Finally, it was estimated that optogenetic pacemakers would require less 
energy that could prolong the battery lifespan of implantable devices and reduce re-implantation 
28urgeries.112,128  
 
 
Figure 8: Optogenetic pacing of wild type hearts after AAV mediated gene transfer. (A) Epicardial view 
of a mouse heart four weeks after systemic injection of AAV encapsulated with proteins from the 
serotype 9 for expression of ChR2 in fusion to the red fluorescence protein mCherry. Fluorescence 
signals (red) indicate ChR2 expression (bar = 1 mm). (B) Pulsed illumination (indicated by blue lines: 
470 nm, 20 ms, 0.5 mW/mm2) focused on the anterior part of the ventricles (25 mm2) allows stable 
optical pacing in vivo. Inserts show the different QRS shape of extrasystoles and the retrograde p-wave 
during optical pacing (2) in contrast to the sinus rhythm (1). Figures are adapted and modified from Vogt 
CC et al., Cardiovascular Research 2015.126 
 
In conclusion, optogenetic stimulation of cardiomyocytes and the intact heart has been 
demonstrated several times and allows completely new experiments to address unsolved 
questions in cardiac electrophysiology. In addition, AAV based gene transfer could enable in 
principle optogenetic stimulation in human hearts and presents a potential new treatment option. 
 
2.3.3.2 Optogenetic stimulation of skeletal muscle 
Indirect optogenetic stimulation of skeletal muscle through the motor neuron system was 
demonstrated by illumination of ChR2 expressing neurons in the motor cortex which triggered 
movement of the whiskers129 and locomotion in freely moving mice.102 Soon afterwards, it was 
reported that optogenetic stimulation of the phrenic motor neuron restored movement of the 
diaphragm and was able to restore breathing in rats after spinal cord injury.130 Furthermore 
indirect optogenetic stimulation of skeletal muscles was also achieved by illuminating 
peripheral ChR2expressing nerves in transgenic animals131 and in wild type mice after AAV 
injection132 or after transplantation of ChR2 expressing embryonic stem cell derived neurons.133 
Interestingly, optogenetic technology was also used to prevent AP propagation and inhibit 
muscle activation by expressing the Cl- pump Halorhodopsin in motor neurons.134 Thus indirect 
control of skeletal muscles was demonstrated by stimulating all parts of the motor nerve tract.24  
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However, such indirect stimulation cannot be used to investigate excitation contraction 
coupling in skeletal muscles or to analyze possible feedback mechanisms from skeletal muscles 
to the innervating nerves. The first direct non-neuronal stimulation of skeletal muscles was 
demonstrated in the nematodes Caenorhabditis elegans:61ChR2 was expressed within the body 
wall and the egg-laying muscles and illumination of the whole animal simultaneously induced 
contraction of the whole body including egg expulsion. In mammalian system, direct 
stimulation of skeletal muscles was first demonstrated in vitro in C2C12 cells, which are 
immortalized myoblasts from mice. After differentiation and cell-fusion, C2C12 cells can form 
myotubes with some contractile function.135,136 Pulsed illumination of ChR2 expressing C2C12 
myotubes was shown to induce contractions. Global illumination results thereby in a 
homogenous depolarization of the cell membrane.137 Focusing light on only small parts of the 
membrane was used to test the excitability at this site and to analyze how local membrane 
depolarization propagates along the sarcolemmal surface.138 Interestingly, long term 
optogenetic stimulation induced preliminary maturation in C2C12 myotubes detected by a 
higher percentage of myotubes with sarcomeric structures, contractility and a slight reduction 
of the resting membrane potential.139 In addition, optogenetic stimulation of C2C12 myotubes 
can improve movements of robotic actuators because it enables fine grain control of force and 
selective stimulation of different parts within the robotic muscle tissue.140 The concept of 
optogenetic muscle actuators for robotic movement was demonstrated by two recent studies: 
The first study demonstrated bidirectional movement of bioactuators and the advantage that the 
generated force can be controlled over a wide range.141 The second study showed the generation 
of a complete artificial fish-like robot built from dissociated ChR2 expressing rat 
cardiomyocytes engrafted into a microfabricated gold skeleton. A tightly controlled sequence 
of illumination patterns even allowed to guide the robotic fish through an obstacle course by 
phototactic steering.142 Taken together, direct stimulation of skeletal myotubes could be 
demonstrated in vitro but the feasibility and especially efficacy to stimulate intact skeletal 
muscles has never been tested. 
 
2.3.4 Optogenetic technologies for therapeutic approaches  
The ability of optogenetics to perform cell-specific stimulation with high spatial control has 
soon led to tantalizing proposals for treatment of patients. The general feasibility of several 
approaches has been demonstrated in small animal models including restoration of vision,62 
cochlear implants,143 pain inhibition in peripheral nerves,103 control of blood glucose 
levels,144,145 as well as restoring urinary bladder contraction146 and treating erectile 
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dysfunction.80 Among these, the most promising approach that was soon suggested after the 
discovery of ChR2 was to restore visual perception in cases of Retinitis pigmentosa,62 a disease 
which leads to irreversible degeneration of the directly photosensitive cells in the retina. Ever 
since, many groups have tried different approaches towards this ambitious aim147-150 and in 
2017 the first clinical trial was approved by the food and drug administration of the United 
States (FDA).  
All therapeutic approaches face similar challenges. A safe way to express the light-sensitive 
protein in cells of interest is most important. Until today, it remains unresolved whether the 
overexpression of the non-human ChR2 proteins in vivo will be detected by the immune system 
and could trigger an immune response. In fact, injection of AAV to express ChR2 in the retina 
of rats led to antibody production against the AAV as well as against ChR2.151 However this 
was not associated with histological changes or loss of vision. Taking into account that the eye 
is an immunological privileged region, these results cannot be transferred to other applications. 
Once ChR2 expression is solved, sufficient illumination in situ is required but can be technically 
challenging especially in regions of the body which are moving. For this purpose, several 
biotechnological advancements in the recent years have resulted in promising options. Among 
these are cell-scale injectable LEDs152-154 which can be integrated in stretchable integumentary 
membranes155 or the development as well as the application of µLED arrays.156 Taken together, 
optogenetic stimulation and its intrinsic technical advantages propose new strategies for clinical 
treatments. However implantation of light emitting devices, the required gene transfer and the 
expression of previously extraneous proteins are major obstacles which have to be solved before 
entering clinical trials.  
 
3. Optogenetic defibrillation  
3.1 Prologue 
Currently, defibrillation by electrical shocks is the only acute therapeutic option to rescue 
patients from life-threatening ventricular tachyarrhythmia. However the mechanism 
responsible for the termination of the arrhythmia by the electrical shock is still poorly 
understood. This is mainly because the effects of electrical stimulation cannot be predicted 
within the heart with its complex structure and electrical anisotropy resulting in de- and 
hyperpolarized areas. Thus most mechanistic investigations on defibrillation are restricted to 
analyses of correlative observations or computer simulations of the heart.157 Several principles 
have been suggested to be the underlying mechanism for successful defibrillation by 
depolarization such as filling of the excitable gap,158,159 prolongation of the refractory period160 
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and conduction block.161 Furthermore, also the hyperpolarization has been discussed to play a 
crucial role.162 To unravel the importance of each suggested mechanism, a novel method is 
required which can evoke de- and hyperpolarization separately in specific areas with well-
defined timings. Optogenetic stimulation would allow such experiments and the advantage of 
this technology for the investigation of defibrillation has already been demonstrated in vitro. 
We have shown that regional illumination of a spontaneously beating monolayers induces a 
conduction block.91 Others have used optogenetic depolarization to reduce the excitability, slow 
conduction and thereby terminate re-entrant wave fronts in a monolayer of rat 
cardiomyocytes.119 In addition, specific illumination patterns were used to inscribe excitation 
waves, to control the direction of conduction and to destabilize the reentry wave fronts in 
cardiomyocyte monolayers.163 Finally, initial computer simulations of a human heart suggested 
optogenetic defibrillation with red light sensitive ChRs and illumination from the endo- and 
epicard.164 While all these in vitro and in silico experiments delivered tantalizing results, they 
are unsuited to predict the feasibility of optogenetic defibrillation within the intact heart. The 
main question was whether the light could penetrate through all layers of the myocardium to 
depolarize a sufficient amount of cardiac tissue. Computer simulation were performed to predict 
the physical penetration of light estimating the residual light intensities for the myocardial 
layers in dependence to the applied light intensity at the epicardium.165 However in addition to 
light scattering and attenuation, the resulting depolarizing effect could only be roughly 
estimated because of the unpredictable influence of the electrical coupling and the local 
anatomical structure. Furthermore, the amount and local extent of depolarization required for 
successful optogenetic depolarization is not known. Besides addressing the mechanism of 
defibrillation, optogenetic defibrillation would provide a tempting outlook for the treatment of 
ventricular arrhythmia because in contrast to electrical shocks, optogenetic stimulation could 
be performed pain-free and would be less damaging. Therefore, we explored the practicability 
and requirements of optogenetic defibrillation in intact hearts of mice. In addition, we translated 
the results generated in mouse hearts to a computer simulation of an infarcted human heart to 
identify the requirement for therapeutic applications of optogenetic defibrillation by epicardial 
illumination. 
3.2 Original publication 
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Introduction
Ventricular tachycardia (VT) and ventricular fibrillation (VF) 
are malignant arrhythmias, which are characterized by fast and 
uncoordinated electrical excitations of the myocardium, result-
ing in pump failure and leading to sudden cardiac death. The 
current state-of-the-art therapy for these life-threatening dis-
orders is defibrillation by the delivery of high-energy electrical 
shocks. Patients at risk for developing ventricular arrhythmia 
receive implantable automatic defibrillators. Clinical studies 
have demonstrated the life-saving potential of this therapeutic 
approach; however, it is also associated with significant adverse 
effects, such as structural damage of cardiac tissue worsening 
the underlying cardiac disease, severe pain due to nonselective 
excitation of nerves and muscles with subsequent psychological 
trauma, and increased mortality (1–4). Thus, there is a need for 
alternative approaches that enable pain-free and less deleterious 
termination of lethal arrhythmia.
Optogenetics is an emerging technology that enables mod-
ulation of electrical function with light in cells overexpressing 
light-sensitive proteins. The light-activated cation channel chan-
nelrhodopsin-2 (ChR2) has been used to directly pace the heart 
with brief (1–10 ms) blue light pulses in vivo (5–8). However, 
these results do not imply the feasibility of optogenetic defibril-
lation, because cardiac pacing entails only a brief depolarization 
in a few cardiomyocytes with subsequent intrinsic excitation of 
the whole heart through gap-junctional electrical coupling. In 
contrast, defibrillation requires the simultaneous depolarization 
of a large mass of ventricular tissue (9), and therefore the energy 
required for a defibrillating shock is dramatically larger than that 
of a typical pacing stimulus. Optogenetics enables the selective 
depolarization of ChR2-expressing cardiomyocytes only, making 
it an attractive pain-free alternative to electrical shocks. An addi-
tional strength over electrical shocks is that optogenetics allows 
uniform and sustained depolarization by continuous illumination. 
Although this advantage has been exploited in vitro to achieve 
fine-grain control of excitation waves in cardiomyocyte monolay-
ers, including reentry destabilization (10), slowing of conduction 
(11), and suppression of electrical activity (5), the feasibility of 
optogenetic defibrillation in intact hearts has never been demon-
strated experimentally.
Herein, we report a new protocol to induce sustained ventricu-
lar arrhythmia in mouse hearts and provide experimental evidence 
that optogenetic defibrillation by illumination of the epicardial sur-
face is a highly reliable approach. In addition, we investigate the 
translational potential of optogenetic defibrillation by epicardial 
illumination with a novel in silico approach using a model of the 
heart of a patient with a propensity for infarct-related VT.
Results
Optogenetic defibrillation via epicardial illumination in intact hearts 
of transgenic mice. First, we explored optogenetic defibrillation via 
epicardial illumination in hearts of transgenic mice expressing 
ChR2 in all cardiomyocytes (5). Because of the small size of the 
Ventricular arrhythmias are among the most severe complications of heart disease and can result in sudden cardiac 
death. Patients at risk currently receive implantable defibrillators that deliver electrical shocks to terminate arrhythmias 
on demand. However, strong electrical shocks can damage the heart and cause severe pain. Therefore, we have tested 
optogenetic defibrillation using expression of the light-sensitive channel channelrhodopsin-2 (ChR2) in cardiac tissue. 
Epicardial illumination effectively terminated ventricular arrhythmias in hearts from transgenic mice and from WT mice 
after adeno-associated virus–based gene transfer of ChR2. We also explored optogenetic defibrillation for human hearts, 
taking advantage of a recently developed, clinically validated in silico approach for simulating infarct-related ventricular 
tachycardia (VT). Our analysis revealed that illumination with red light effectively terminates VT in diseased, ChR2-expressing 
human hearts. Mechanistically, we determined that the observed VT termination is due to ChR2-mediated transmural 
depolarization of the myocardium, which causes a block of voltage-dependent Na+ channels throughout the myocardial wall 
and interrupts wavefront propagation into illuminated tissue. Thus, our results demonstrate that optogenetic defibrillation 
is highly effective in the mouse heart and could potentially be translated into humans to achieve nondamaging and pain-free 
termination of ventricular arrhythmia.
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second, 0.4 mW/mm2, 143 mm2; Supplemental Figure 1B) resulted 
in arrhythmia termination with an average success rate of about 
85%, independent of the preceding arrhythmia duration (3, 5, or 
10 seconds; Figure 1B, blue). Control experiments without illumi-
nation showed that the rate of spontaneous arrhythmia termina-
tion in the same time window was very low (<15%, P < 0.04; Figure 
1B, black). To further enhance optogenetic defibrillation efficacy, 
we developed an illumination protocol involving 4 consecutive 
light pulses (1 second, 0.4 mW/mm2, 143 mm2; Supplemental Fig-
ure 1C), which yielded a very high success rate of 97% ± 0.01% (n 
= 29; Figure 1C, blue). Importantly, when the identical illumina-
tion protocol was applied to hearts without ChR2 expression from 
EGFP-expressing or CD1 WT mice, the arrhythmia termination 
rate in the same time window was approximately 20% (Figure 1C, 
green and red). This value is similar to the spontaneous termina-
mouse heart, electrically induced ventricular arrhythmias in vivo 
are often self-terminating after several cycles (12), rendering the 
analysis of defibrillation efficacy impossible. Therefore, we devel-
oped a novel protocol and obtained sustained ventricular arrhyth-
mias evoked by electrical burst stimulation or S1-S2 protocols 
from the base of the right ventricular wall at a point with minimal 
effective refractory period (ERP) in hearts perfused ex vivo with 
low-K+ (2 mM) Tyrode’s solution and the KATP channel activator 
pinacidil (100 ȝM; Supplemental Figure 1A; supplemental mate-
rial available online with this article; doi:10.1172/JCI88950DS1). 
Termination of ventricular arrhythmia was achieved by illumi-
nation of the anteroseptal epicardium with blue light (470 nm) 
in all hearts tested (n = 36; Figure 1A). These results reveal that 
uniform light- induced depolarization is sufficient for cardiac 
defibrillation. Quantitatively, application of 1 single light pulse (1 
Figure 1. Optogenetic defibrillation in transgenic hearts. (A) Representative ECG (black) from an explanted heart expressing ChR2. Sustained VT was 
induced by electrical burst stimulation (50 Hz, red bar) and terminated by epicardial illumination with blue light (blue bar, 470 nm, 1 second, 0.4 mW/mm2, 
143 mm2, n = 36). (B) Arrhythmia termination rate in ChR2 hearts after one 1-second-long light pulse (0.4 mW/mm2, 143 mm2, blue) applied 3, 5, and 10 
seconds after induction of arrhythmia compared with control conditions (i.e., no illumination, black) in the same time window (see Supplemental Figure 1B 
for experimental protocol; Wilcoxon matched pairs test, P < 0.04, n = 6). (C) Arrhythmia termination rate in response to a 4-light-pulse protocol (Supple-
mental Figure 1C) in ChR2 mouse hearts with illumination (1 second, 0.4 mW/mm2, 143 mm2, blue) and without illumination (black), as well as in hearts 
expressing only EGFP (green) and in CD1 WT hearts (red) with illumination (Kruskal-Wallis test, P < 0.0001, with Dunn’s multiple-comparison post-test; 
ChR2 light: n = 29; ChR2 no light: n = 6; EGFP: n = 4; CD1 WT: n = 6). (D–F) Influence of illumination duration (D, 0.4 mW/mm2, 29 mm2, n = 7, P = 0.0007), 
area (E, 1 second, 0.4 mW/mm2, n = 9, P = 0.031), and light intensity (F, 1 second, 15 mm2, n = 5, P = 0.013) on arrhythmia termination rate (Friedman test). 
Each point shows the percentage of successful optogenetic defibrillation attempts in 1 heart. Data are shown as the mean ± SEM.
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therapeutic applications in humans. We previously used adeno- 
associated virus (AAV) with tropism toward cardiomyocytes 
systemically injected into WT mice and found ChR2 expression 
in approximately 58.2% of cardiomyocytes 4 to 8 weeks later, 
enabling optogenetic cardiac pacing (6). With the same approach, 
1 year after AAV injection we found uniform ChR2 expression 
throughout the ventricles (Figure 3A) and in all myocardial layers 
(Figure 3B), localized to the sarcolemma and the T-tubule system 
of cardiomyocytes (Figure 3C). In vivo optogenetic pacing exper-
iments (5, 6) in these hearts demonstrated stable ventricular pac-
ing 1 year after the AAV injection with a threshold of 0.64 ± 0.20 
mW/mm2 (Figure 3D; 10 ms pulse duration, 15 mm2 illuminated 
area, n = 3). This value is similar to our previously reported data for 
optogenetic pacing 4–8 weeks after injection of AAV (6). Impor-
tantly, we also tested optogenetic defibrillation ex vivo 1 year after 
the AAV injection. Therefore we induced ventricular arrhythmia 
after low K+ (2 mM) and pinacidil perfusion and found that illumi-
nation (1 second, 0.4 mW/mm2, 143 mm2) of the anteroseptal epi-
cardium reliably terminated ventricular arrhythmia in all 3 tested 
mice (Figure 3E).
Optogenetic defibrillation via epicardial illumination in a mod-
el of a patient heart. In order to explore whether our findings in 
mice could be translated to human hearts for potential clinical 
applications, we conducted computer simulations of optical 
defibrillation by epicardial illumination in the heart of a patient 
suffering recurrent VT. The model (Supplemental Figure 2) 
was reconstructed from a late gadolinium enhancement MRI 
scan of a patient with myocardial infarction and VT episodes 
that required defibrillator implantation. Consistent with clin-
ical observations, rapid electrical pacing from the ventricular 
apex in this model induced infarct-related, sustained VT (cycle 
length: ~350 ms; Supplemental Figure 3 and Supplemental Video 
1), which was evident in the pseudo-ECG (Figure 4A). Based on 
expression levels in our previous reports on AAV gene transfer 
(6), we simulated expression of ChR2 in 58.2% of the cardiomy-
ocytes (Supplemental Figure 4) using an optogenetic modeling 
framework (13) validated by comparison with in vitro recordings 
from ChR2-expressing cardiomyocyte syncytia (14). The ChR2 
tion rate in the absence of illumination in transgenic ChR2 hearts 
(Figure 1C, black). Thus, neither illumination of ChR2-negative 
hearts nor ChR2 expression in the absence of illumination caused 
or facilitated arrhythmia termination.
To determine how different illumination parameters affect 
defibrillation success rates, sequential protocols with light stimu-
li of varying duration, intensity, and size of illuminated area were 
tested (Supplemental Figure 1, A and C). This revealed a signifi-
cant influence of light stimulus duration, and the defibrillation 
rate was low for durations less than 100 ms (Figure 1D), suggest-
ing that illumination lasting for at least the duration of the entire 
VT cycle (~80 ms) was required for successful arrhythmia termi-
nation. Decreasing the illuminated area to 15 mm2 also reduced 
efficacy (Figure 1E), and in this situation the light intensity needed 
to effectively defibrillate increased from 0.4 to 1 mW/mm2 (Fig-
ure 1F). This suggests that optogenetic depolarization of a critical 
portion of myocardium was necessary to successfully defibrillate.
Optogenetic defibrillation after acute myocardial infarction. To 
experimentally assess the feasibility of optogenetic defibrillation 
in a scenario clinically more relevant to the underlying causes of 
life-threatening arrhythmia in humans, we determined whether 
infarct-related arrhythmia could be terminated by light. There-
fore, hearts from ChR2 mice were perfused ex vivo with stan-
dard Tyrode’s solution, and the left anterior descending coronary 
artery was ligated (Figure 2A, arrow). This led to acute myocardial 
ischemia, which was proven by ST-segment elevation in the ECG 
(Figure 2B) and by the lack of local perfusion documented by dye 
injection after the experiment (Figure 2A). Prolonged ventricular 
arrhythmia could be induced by electrical pacing in 6 of the 12 
hearts investigated. In these 6 hearts we found that a single light 
pulse (1 second, 0.4 mW/mm2, 143 mm2) could terminate arrhyth-
mia (Figure 2B) with a success rate of 88% ± 0.04% in contrast 
to the significantly lower rate of spontaneous termination in the 
absence of illumination (27% ± 0.07%, P = 0.03; Figure 2C).
Optogenetic defibrillation in WT hearts after gene transfer. After 
establishing the feasibility of optogenetic defibrillation in trans-
genic mice, we sought to test the same approach in nontransgenic 
hearts after gene transfer in vivo, since this would be required for 
Figure 2. Optogenetic defibrillation of infarct-related ventricular arrhythmia in ChR2-expressing hearts. (A) Image of the whole heart after ligation of 
the left anterior descending coronary artery (red arrow) and dye perfusion (blue), highlighting the nonperfused infarct area. (B) Representative ECG (black) 
after ligation. Note the prominent elevation of the ST segment during normal sinus rhythm. Ventricular arrhythmia was induced by electrical burst stimu-
lation (50 Hz, red bar) and terminated by epicardial illumination with blue light (blue bar, 470 nm, 1 second, 0.4 mW/mm2, 143 mm2, n = 10). (C) Arrhythmia 
termination rate in infarcted hearts induced by one 1-second-long light pulse (0.4 mW/mm2, 143 mm2, blue) applied 5 seconds after induction of arrhyth-
mia compared with control (i.e., no illumination, black) within the same time window (see Supplemental Figure 1B for experimental protocol; Wilcoxon 
matched pairs test, P = 0.031, n = 6). Scale bar: 1 mm. Data are shown as the mean ± SEM.
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the excitability of the illuminated myocardial wall. Importantly, 
the deepest layer in which red light depolarized at least 75% of all 
cardiomyocytes beyond the threshold to inactivate 90% of Na+ 
channels (Vm = –65.8 mV) was 6 mm from the epicardium (Figure 
5D, red arrow). Consequently, the wavefront emerging from the 
isthmus of the re-entrant circuit, located in the nonilluminated 
ventricular septum, could not propagate through the optogeneti-
cally depolarized right ventricular free wall, thereby leading to VT 
termination (Figure 5E and Supplemental Video 3).
To verify that transmural depolarization is critical for optoge-
netic defibrillation, we simulated epicardial illumination with blue 
light, which is much more attenuated by heart tissue (Supplemen-
tal Figure 5) (20). In fact, blue light (488 nm) triggered an initial 
epicardial excitation, which propagated transmurally and induced 
the above-defined degree of depolarization to block Na+ channels 
only within 1 mm of the epicardial surface (Figure 5D, blue arrow, 
and Supplemental Figure 6A). Therefore, the excitation wave-
front emerging from the septum was able to propagate through 
the endocardial layer of the right ventricular free wall, sustaining 
re-entrant propagation (Supplemental Figure 6, B and C, and Sup-
plemental Video 2 and 3).
Modeling of pericardial illumination. Since illumination of the 
pericardium, rather than direct application of light to the epicar-
dium, will be practically more feasible, we performed addition-
al calculations to assess how the tissue layers surrounding the 
human heart would attenuate light. First, we considered layers of 
epicardial fat and pericardium assuming uniform thickness based 
on values previously reported for these layers in humans (4.1 and 
1.7 mm, respectively) (21, 22). We found that the intensity of a 
pericardial light stimulus would need to be 4.7-fold higher than 
the target intensity on the epicardium in order to overcome atten-
uation in the fibrous and adipose layers covering the heart (Sup-
plemental Figure 7A). Since individual and regional variability in 
epicardial fat thickness has been reported (21), we analyzed the 
consequences and found a required increase in pericardial light 
stimulus strength from approximately 2-fold in the absence of fat 
to approximately 10-fold when the adipose tissue layer was 8 mm 
thick (Supplemental Figure 7B).
Discussion
Herein we demonstrate effective optogenetic defibrillation in the 
intact mouse heart by epicardial illumination. To enable these 
experiments, we had to establish a new approach to reliably induce 
sustained ventricular arrhythmia in the small mouse heart, which 
normally lasts only a few seconds in vivo (12). Our approach is to 
perfuse explanted mouse hearts with low-K+ solution, which is 
known to promote arrhythmias (23), and pinacidil, which activates 
photocurrent model (15) was calibrated to match measurements 
from AAV-transfected mouse cardiomyocytes (6).
We have recently shown in computer stimulations that for 
optogenetic defibrillation of a structurally normal heart by simul-
taneous epicardial and endocardial illumination, red light and 
increased opsin light sensitivity (increased 2.2-fold vs. normal 
ChR2) are needed (16). These changes are consistent with the bio-
physical properties of red-shifted ChR2 variants (17, 18) and the 
CatCh variant of ChR2 (19), respectively. Accordingly, to assess 
the feasibility of light-based defibrillation in the more complex 
setting of a patient heart with structural and electrophysiological 
heterogeneities, we performed simulations with the same opto-
genetic parameters. However, epicardial-only illumination was 
simulated, because the feasibility of endocardial illumination is 
questionable. Our simulations revealed that exclusive illumina-
tion from the epicardium with red light (1 second, 10 mW/mm2, 
669 nm) effectively terminated the sustained VT (Figure 4, B and 
C, and Supplemental Video 2).
Critical biophysical determinants for optogenetic defibrillation. 
Next, we investigated the critical factors underlying successful 
optogenetic defibrillation by analyzing membrane potential (Vm) 
traces from epicardial, midmyocardial, and endocardial sites 
during simulated illumination (Figure 5A). Our analysis revealed 
simultaneous transmural excitation upon illumination, followed 
by strong diastolic depolarization (~−40 mV) that affected all lay-
ers (Figure 5B) and completely abrogated Na+ channel excitabil-
ity, even in the endocardial layer (Figure 5C). Therefore, action 
potential initiation during illumination became purely Ca2+ cur-
rent–dependent (Figure 5C), resulting in a critical decrease in 
Figure 3. Optogenetic pacing and defibrillation in hearts 1 year after in 
vivo gene transfer. (A) Epicardial mCherry fluorescence signal of a mouse 
heart 16 months after systemic injection of ChR2-mCherry AAV. (B) Section 
through the left ventricle showing transmural mCherry fluorescence. (C) 
Membrane-bound ChR2-mCherry signals in a ventricular cardiomyocyte. 
(D) Pulsed illumination (blue dots, 470 nm, 10 ms, 0.36 mW/mm2, 15 
mm2, n = 3) of the left ventricle in vivo induced ectopic ventricular pacing, 
as shown in the ECG (black). (E) VT episode was terminated by epicardial 
illumination (470 nm, 1 second, 0.4 mW/mm2, 143 mm2, n = 3) of the ven-
tricles. Scale bars: 1 mm (A and B) and 20 ȝm (C); nuclear staining in blue.
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Figure 4. Optogenetic defibrillation 
in a model of a patient heart with 
infarct-related VT. (A and B) Pseu-
do-ECG signals for model configurations 
with no illumination (A) and epicardial 
illumination with red light (669 nm, 
10 mW/mm2, 1 second, red box, B). VT 
was induced by electrical stimulation 
(yellow triangles). (C) Snapshots of Vm 
distribution during the response to red 
light. Timings (from start of simulation) 
correspond to dashed lines in B. The 
right ventricular free wall is cut away 
to facilitate visualization. Black arrows 
indicate propagation of reentry during 
VT (see also Supplemental Figure 3 and 
Supplemental Videos 1 and 2); red trian-
gles indicate initial excitations induced 
directly by optogenetic stimulation.
strated the in silico approach to simulate this type of arrhythmia 
and its predictive power and clinical relevance, by predicting, 
with high accuracy and reliability, postinfarction risk of sudden 
cardiac death in a cohort of 41 patients (27). Here, in contrast to 
our recent modeling of optogenetic defibrillation in structurally 
normal ventricles (16), we exclusively illuminated the epicardi-
al surface. This is because intracavitary optogenetic stimulation 
of the endocardium would be extremely challenging because of 
the presence of light-absorbing blood, the need for anticoagula-
tion, and the difficulty of implanting light-emitting diodes (LEDs) 
within the densely trabeculated endocardium of the beating heart 
without compromising ventricular function or hemodynamic sta-
bility. Conversely, illumination of the epicardium in the human 
heart could be achieved by leveraging new developments in opto-
electronics, such as light sources integrated in cell-scale injectable 
devices (28) or stretchable integumentary membranes, which 
have been proven useful for illumination of the heart (29). More-
over, because direct epicardial implantation of light sources will 
be associated with risks of infection, pericarditis, friction, or coro-
nary artery damage, we anticipate that illumination in the human 
heart would be more feasible from the pericardial surface. Thus, 
we performed mathematical analysis to approximate the extent of 
light attenuation in the pericardium and epicardial fat and found 
that the intensity of light applied to the pericardium would need 
to be increased approximately 5-fold compared with direct epicar-
dial illumination. However, excessive epicardial fat would greatly 
attenuate light and thus diminish the effectiveness of optogenetic 
defibrillation by pericardial illumination.
The new mechanistic insights presented here suggest that 
ventricular arrhythmia can be terminated not only by electrical 
shock–induced brief excitation, but also by a steady-state opto-
genetic modulation of electrical activity involving transmural 
depolarization and Na+ channel inactivation. Importantly, our 
simulations clearly demonstrate that transmural depolarization 
depends critically on effective light penetration. This parameter 
is influenced greatly by the wavelength dependency of light pen-
etration and, to a lesser degree, by ChR2 light sensitivity, pho-
tocurrent, or expression levels. Thus sufficient transmural depo-
the ventricular Kir6.2/SUR2A KATP channels (24) and thus mim-
ics pro-arrhythmic effects of ischemia, including action potential 
shortening and dispersion of repolarization and refractoriness 
(25). The ex vivo retrograde perfusion of the coronary arteries in 
the Langendorff configuration has the distinct advantage of con-
stant oxygen and nutrition supply even during long episodes of 
sustained ventricular arrhythmia, enabling multiple defibrillation 
attempts for systematic analysis of defibrillation success rate.
Epicardial illumination proved to be highly efficient in all 
ChR2-expressing mouse hearts tested in terminating ventricular 
arrhythmias, the ECG patterns of which resembled those of VT, 
torsades de pointes, and VF. By comparing light-induced and 
spontaneous arrhythmia termination in ChR2-expressing hearts 
and by investigating control hearts without ChR2, we proved 
unequivocally that neither illumination nor ChR2 expression per 
se is sufficient for arrhythmia termination. Instead, optogenet-
ic defibrillation is achieved by light-induced depolarization of 
ChR2-expressing cardiomyocytes. We found that optogenetic 
defibrillation required higher light intensities, longer durations, 
and larger illumination sizes compared with optogenetic pacing 
(5), reflecting the clear mechanistic difference between pacing, for 
which local depolarization is sufficient, and defibrillation, which 
requires depolarization of a much larger tissue volume (9). This 
requirement of defibrillation was proven in earlier work by selec-
tive coronary injection of potassium chloride, demonstrating that 
VF in canines could only be terminated when a critical amount 
of myocardium was depolarized (9). Our findings are consistent 
with these experiments because diminishing the illumination area 
reduced the efficacy of optogenetic defibrillation.
Although our experimental work here demonstrated the effi-
cacy of optogenetic defibrillation after acute myocardial infarction 
and after AAV-based ChR2 gene transfer of WT mice, it is difficult 
to extrapolate these results to the human heart. Thus, the next step 
will be the extension of this technology to preclinical large-ani-
mal models with electrical and structural defects comparable to 
the human heart. As a preliminary proof-of-concept exploration 
in humans, we simulated optogenetic defibrillation in a human 
model of infarct-related VT (26). Our group has recently demon-
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larization at low light intensities will be facilitated by exploiting 
recent advances in optogenetics, like red-shifted and hypersen-
sitive ChR2 variants (17–19).
The fact that optogenetic defibrillation in human diseased 
hearts is feasible using only epicardial illumination and that car-
diac gene expression via AAV in humans is safe (30) suggests the 
tantalizing possibility that clinical applications might be feasible. 
Importantly, we were able to demonstrate effective pacing and 
defibrillation of mouse hearts by epicardial illumination even more 
than 1 year after the gene transfer. The great advantage of optoge-
netic defibrillation is that this would be, in contrast to electrical 
shocks, pain-free, because ChR2 expression would be restricted 
to cardiomyocytes by cardiomyocyte-specific AAV vector capsids 
(30) or promoters (31). Notably, AAV-mediated transduction will 
result in spatial heterogeneity of ChR2 expression, which is not 
expected to be pro-arrhythmic per se since ChR2 has neither a 
leak current in the absence of illumination nor does it affect the 
electrophysiological properties of cardiomyocytes (5). During illu-
mination, however, non-uniformities in either ChR2 expression or 
light application could result in heterogeneous excitation patterns, 
which might have secondary pro-arrhythmic consequences (e.g., 
reinitiation of VT/VF) in addition to the primary effect of optoge-
netic defibrillation. Fortunately, in contrast to electrical shocks, 
light stimuli used for optogenetic defibrillation have a much high-
er degree of flexibility, because spatially and temporally shaped 
light patterns minimizing secondary pro-arrhythmic effects could 
be used. Moreover, unlike defibrillation shocks, sequential light 
pulses can be applied repetitively, as these do not require the 
charging of a capacitator to generate high-voltage fields. In fact, 
our experimental results in mouse hearts showed that 4 consec-
utive light pulses instead of 1 increased the termination rate from 
85% to 97%. Importantly, the optogenetic modeling approach pre-
sented here makes it possible to predict in silico the effectiveness 
of novel red-shifted ChR2 variants, gene transfer strategies, or 
illumination technologies before conducting large animal exper-
iments in vivo and before proposing individualized clinical trials, 
Figure 5. Mechanism of optogenetic defibrillation in the human heart. (A) Illustration of the locations of sites 1–3 on the right ventricular posteroseptal 
wall. (B) Vm traces from sites 1–3 during epicardial illumination with red light (669 nm, 1 second, 10 mW/mm2, red box) Dashed lines indicate Vm = 0. (C) 
Ionic Na+ (INa) and L-type Ca
2+ (ICa,L) currents underlying Vm from endocardial site 3 in B. (D) Minimum diastolic Vm values during illumination with blue (488 
nm) and red light as a function of depth in the ventricular free walls. Upper quartile, median, and lower quartile values are shown. Blue and red arrows 
indicate the deepest tissue layers in which more than 75% of cardiomyocytes had a minimum diastolic Vm exceeding the threshold for 90% inactivation 
of Na+ current (Vm = –65.8 mV, dashed line). (E) Zoomed-in snapshots of Vm distribution during the illumination at the indicated time points from start of 
simulation (see also Supplemental Video 3). Snapshots were taken from the region shown in A (black rectangle, in top panel). 
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e.g., for therapy-resistant patients who experience frequent pain-
ful electrical shocks from implanted defibrillators.
Methods
Animals. Experiments on transgenic ChR2-expressing mice were per-
formed with 23 males (aged 4–15 months, median 6 months) and 27 
females (aged 3.5–14.5 months, median 4.5 months) from a previously 
established mouse line (5) expressing ChR2 with the H134R mutation 
(32) under the control of the chicken ȕ-actin (CAG) promoter and back-
crossed at least 10 generations onto a CD1 genetic background. The 
CAG-EGFP mouse line was reported before (5), backcrossed at least 10 
generations onto a CD1 genetic background, and we used five 2.5- to 
3.5-month-old females. From the CD1 WT strain (Charles River) we 
used 7 female mice 6.5 to 12 months old as controls and three 10-week-
old female mice for ChR2 gene transfer by systemic injection of AAV.
Optogenetic defibrillation. Mice were heparinized and sacrificed 
by cervical dislocation. Hearts were explanted and perfused in Lan-
gendorff configuration with Tyrode’s solution containing (in mM) 140 
NaCl, 5.4 KCl, 1.8 CaCl2, 2 MgCl2, 10 glucose, and 10 HEPES (pH 7.4, 
adjusted with NaOH). A bipolar cardiac electrogram was recorded 
with a silver chloride electrode placed at the right atrium and a met-
al spoon under the apex of the heart using a bio-amplifier recording 
system (PowerLab 8/30, Animal Bio Amp ML 136, LabChart 7.1 soft-
ware, AD Instruments). Electrical stimulation (1–10 mA, 2 ms) was 
applied via a bipolar silver chloride electrode (<3 mm distance) placed 
epicardially. The local effective refractory period (ERP) was deter-
mined using an S1-S2 protocol, with 6 stimuli at a cycle length of 150 
ms (S1) followed by a premature stimulus (S2) with a variable delay 
(<150 ms) that was decreased in 5-ms increments. The shortest delay 
for successful S2 pacing was defined as the local ERP. The electrode 
was relocated until an epicardial site with a low local ERP (<55 ms) 
was identified, because we observed that pacing from such locations 
was the most reliable way to induce ventricular arrhythmia in mouse 
hearts. Application of either electrical burst stimulation (50 Hz, 20–50 
pulses) or an S1-S2 protocol with an S2 delay exceeding the local ERP 
by less than 5 ms evoked free-running ventricular arrhythmia. In stan-
dard Tyrode’s solution, arrhythmia episodes often terminated sponta-
neously after less than 15 seconds. Because sustained arrhythmias are 
required to test optogenetic defibrillation, we lowered the potassium 
concentration to 2 mM and added 100 ȝM pinacidil, which enabled 
induction of sustained (>30 seconds) ventricular arrhythmia. Notably, 
optogenetic defibrillation was attempted in all cases at least 3 seconds 
after induction, which led to inclusion of sustained arrhythmia only 
and exclusion of self-terminating VTs, most of which were shorter 
than 3 seconds. Illumination of the anterior ventricular epicardium 
(Supplemental Figure 1A) was performed with a macroscope (MVX10, 
Olympus) equipped with a 1× objective (MVPLAPO1x, numerical 
aperture 0.25) using 470-nm LEDs (LEDC5 and LEDD1, Thorlabs, 
or GCS-0470-50-A0510 and BLS-13000-1, Mightex) attached to 
the epifluorescence port. LED pulse duration and intensity were con-
trolled and sampled with the bio-amplifier recording system. The spa-
tial extent of the illuminated area was varied using the zoom function 
of the macroscope (Supplemental Figure 1A). Light intensity was cali-
brated by measuring the light power with a power meter (PM100 and 
S130A, Thorlabs) and dividing by the illuminated area. The maximum 
light intensities tested were 0.4, 1.5, and 1.5 mW/mm2 for 143-, 29-, 
and 15-mm2 large circular areas, respectively.
We assessed defibrillation success rates by conducting multiple 
defibrillation attempts per heart using 2 different protocols as follows. 
(a) Single-light-pulse protocol (Supplemental Figure 1B): VT/VF epi-
sodes were allowed to stabilize for 3, 5, or 10 seconds after induction. 
Subsequently, 1 single light pulse (1 second, 0.4 mW/mm2, 143 mm2) 
was applied, and we determined whether it terminated the arrhythmia 
within 4 seconds after the start of illumination (green box in Supple-
mental Figure 1B); otherwise, rescue defibrillation was performed. 
Spontaneous termination rate was analyzed during the same time 
period but without illumination (Figure 1B, black). (b) Four-light-pulse 
protocol (Supplemental Figure 1C): VT/VF episodes were allowed to 
stabilize for 3–15 seconds after induction. Subsequently, 4 light puls-
es with identical illumination parameters were applied with a 1- to 
5-second delay in between, and we determined whether the arrhyth-
mias were terminated between the onset of the first light pulse and 
3–10 seconds after the last illumination (green box in Supplemental 
Figure 1C); otherwise rescue defibrillation was performed. For control 
experiments, the longest illumination protocols were applied to hearts 
from transgenic mice expressing EGFP under the control of the chick-
en ȕ-actin promoter (5) and from CD1 WT mice (Figure 1C, green, 
red). The rate of spontaneous termination in ChR2 mice was assessed 
during the maximum duration of the 4-light-pulse protocol (Figure 
1C, black) but without illumination. The efficacy of the different illu-
mination parameters (pulse duration, illuminated area, and intensity; 
Figure 1, D and E) was analyzed using the 4-light-pulse protocol with 
identical illumination parameters for each of the 4 pulses.
The rescue defibrillation procedure included sequential or 
simultaneous application of high-intensity illumination (145 mm2, 
0.4 to 0.9 mW/mm2, >3 seconds), mechanical force applied to the 
ventricles by tweezers, and/or electrical antitachycardia pacing (50 
Hz, >20 pulses). If this procedure did not terminate the arrhythmia, 
the heart was temporarily perfused with normal Tyrode’s solution 
and, if this restored normal rhythm, optogenetic defibrillation exper-
iments were reattempted.
Acute myocardial infarction. The left anterior descending cor-
onary artery of explanted hearts was ligated with a Prolene 8-0 
thread (Ethicon). Ventricular arrhythmias were induced as reported 
above, but during perfusion with standard Tyrode’s solution. This 
induced prolonged VT/VF episodes (>10 seconds) in 6 of 12 hearts. 
In these hearts, optogenetic defibrillation was tested 5 seconds 
after induction using the single-light-pulse protocol (Supplemental 
Figure 1B), as described above. To verify complete artery ligation, 
hearts were coronary-perfused after the experiment with the food 
dye Patent Blue V E131 (Brauns-Heitmann), and macroscopic imag-
es were taken (see below).
AAV-based gene transfer and optical cardiac pacing. Systemic 
injection of AAV was performed as reported earlier (6). Briefly, the 
AAV9-CAG-hChR2(H134R)-mCherry virus consisting of AAV9 virus 
capsid and AAV2 virus DNA was obtained from the Penn Vector Core 
(University of Pennsylvania) and injected into the jugular vein of 
WT mice anesthetized by inhalation of 1.5% isoflurane and O2/N2O 
(50%/50%). For this purpose, a 5-mm-long cervical incision was per-
formed, 2 × 1011 AAV particles diluted in 100 ȝl of PBS were slowly 
(~10 seconds) injected, bleeding was stopped with forceps and surgical 
swabs, and the skin was sutured (Prolene C-1 13 mm 3/8c, Ethicon).
For optical cardiac pacing in vivo, mice were intubated and venti-
lated with 1.5% to 2.5% isoflurane and O2/N2O (50%/50%) 16 months 
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Simulation of cardiac electrophysiology and numerical methods. Elec-
trophysiology of normal and diseased human cardiac tissue was repre-
sented using an extensively validated approach (35). Briefly, cell- and 
tissue-scale properties were assigned to all 3 regions in the ventricu-
lar mesh: normal myocardium, PIZ, and infarct. At the cell scale, the 
infarcted region was modeled as electrically passive. In the PIZ and 
normal myocardium, action potential dynamics were represented via 
a validated human-specific model (43). In the PIZ, specific modifica-
tions to this model were incorporated to represent electrophysiological 
remodeling observed in patch-clamped myocytes harvested from the 
infarct border zone: fast sodium current (INa) was decreased by 62% 
(44), L-type calcium current (ICa,L) was decreased by 68% (45), and 
delayed rectifier potassium currents (IKr and IKs) were decreased by 
80% and 70%, respectively (46). Consequently, the PIZ action poten-
tial differed from that in the normal myocardium: +16.1% duration, 
–42.2% upstroke velocity, and –42.8% amplitude. These changes were 
consistent with previously reported values (47, 48). At the tissue scale, 
the infarcted region was modeled as nonconductive. In normal myo-
cardium, longitudinal and transverse intracellular conductivity values 
were scaled to 0.255 and 0.0775 S/m, respectively. This resulted in 
longitudinal and transverse conduction velocities (CVL = 59.9 and CVT 
= 33.5 cm/s, respectively) consistent with values measured in experi-
ments with human ventricular tissue (49, 50). In the PIZ, transverse 
intracellular conductivity was reduced by 90% to represent connex-
in-43 remodeling observed in the infarct border zone (51). Because of 
this change and differences in cell-level electrophysiology (as described 
above), PIZ conduction velocities were lower than in normal myocar-
dium (CVL = 49.2 cm/s, CVT = 4.16 cm/s) and had a larger anisotropy 
ratio (11.8:1 vs. 1.79:1). Excitation propagation in the ventricular model 
was modeled via the monodomain formulation as implemented in the 
CARP software (Johns Hopkins University, Université de Bordeaux, 
Medizinische Universität Graz) (52, 53). As described previously (52), 
a leapfrogging approach was used to couple the monodomain partial 
differential equation with the system of ordinary differential equa-
tions that modeled cell-level phenomena. Our previous studies have 
described rigorous validation of this computational framework against 
experimental measurements (14, 34, 54–56). All simulations were exe-
cuted on 24 Intel Haswell CPUs (2.5 GHz) on the parallel computing 
resource at the Maryland Advanced Research Computing Center. The 
total wall time required to simulate 1 second of electrophysiological 
activity in the ventricular model was about 1 hour 40 minutes.
Simulation of channelrhodopsin expression and illumination. To sim-
ulate optogenetic transduction of the human ventricles via viral gene 
delivery, we used our previously validated computational modeling 
framework (13, 14, 57). Channelrhodopsin expression was modeled 
by incorporation of a photocycle model (15) in 58.2% of myocardial 
nodes (normal + PIZ) with a diffuse spatial pattern (Supplemental Fig-
ure 4). This value corresponded to the reported average percentage 
of ChR2-expressing cardiomyocytes in mouse hearts after systemic 
AAV injection (6). The ChR2 channel conductance parameter was cal-
ibrated to 0.17 mS/cm2, resulting in a peak photocurrent of 5.04 pA/
pF when a simulated myocyte clamped to Vm = –52 mV was subject-
ed to blue illumination (5 mW/mm2). This value matched (<1% error) 
recorded peak photocurrent in patch-clamped ChR2-positive myo-
cytes from our earlier study (6). ChR2 light sensitivity was adjusted 
to the CatCh variant (17, 19) by increasing the model rate parameters 
controlling the dark- and light-adapted transitions between closed and 
after the virus injection. To expose the beating heart, the rib cage 
was carefully removed as reported earlier (5, 6). Cardiac ECGs were 
recorded from a needle electrode placed at the right front leg and a 
spoon placed below the heart for stabilization using the bio-amplifier 
recording system (see above). Heart rates were adjusted to 350 to 450 
bpm by varying isoflurane concentration. Optical pacing of the epicar-
dial surface of the left ventricle was performed at a constant frequency 
30 to 50 bpm above basal heart rate using the macroscope and LED 
system (see above). At each light intensity, a train of 40 light pulses 
was applied, and the threshold for optical pacing was defined as the 
minimal light intensity required to achieve 1:1 stimulation for the last 
20 pulses. After in vivo optical pacing, hearts were explanted during 
anesthesia and perfused in Langendorff configuration. Optogenetic 
defibrillation was then tested as described above.
Histology and immunofluorescence. High-resolution macroscopic 
images were recorded from explanted and perfused hearts with an 
AxioZoom.V16 macroscope equipped with a PlanApoZ ×1.0 objective 
lens, a 43 HE filter set, and an AxioCam MRm camera with ZEN 2012 
software (all Zeiss). Images of the curved epicardium were generated 
using Z-stacks and the extended focus module (Zeiss). Hearts were 
fixated by perfusion with 4% paraformaldehyde, dehydrated in 20% 
sucrose, cryopreserved, and sectioned in 10-ȝm-thick slices with a 
cryotome (Cryostat CM3050 S, Leica). Heart slices were permeabi-
lized with 0.2% Triton X (Sigma-Aldrich) for 20 minutes. Nuclear 
staining was performed with 0.1% Hoechst 33342 (Sigma-Aldrich) 
for 1 hour at room temperature. Microscopic pictures were taken 
with inverted fluorescence microscopes (Axiovert 200M) equipped 
with the Apotome section module, a ×20 or ×40 Plan-Apochromat 
objective, AxioCam MRc or MRm camera, ZEN 2012 or AxioVision 
software, a 64 HE filter set (all Zeiss), and an mCherry filter set (F46-
008, AHF Analysentechnik).
Geometrical model of the diseased human ventricles. We used a com-
putational model of the diseased human ventricles reconstructed from 
clinical late gadolinium-enhanced MRI (LGE-MRI) scans of a patient 
with post–myocardial infarction VT (33). The modeling approach has 
been previously validated in infarct-related VT inducibility studies 
(12, 34, 35). Our laboratory pipeline for cardiac model reconstruc-
tion has been described in detail in previous work (12, 34–37). Briefly, 
anatomical landmark points on the epicardial and endocardial walls 
were identified manually in each LGE-MRI slice. These points were 
used as input data for previously described interpolation software, 
which was used to recreate a 3D rendering of the cardiac surfaces. To 
represent the patient’s infarct geometry, tissue within the ventricu-
lar contours on each 2-dimensional LGE-MRI slice was classified as 
diseased or healthy via signal thresholding. Diseased tissue was then 
classified as either peri-infarct zone (PIZ) or infarct using a validated 
full-width half-maximum approach (38). 3D boundaries between the 
3 tissue regions were reconstructed using a shape-based interpolation 
approach (39) that has been validated for use in characterizing myo-
cardial scar (40). We then combined infarct and PIZ contours with the 
rendering of ventricular geometry and used a fully automatic octree-
based technique (41) to generate a boundary-fitted, locally refined, 
smoothed, and conformal 3D mesh (Supplemental Figure 2) suitable 
for finite element modeling of cardiac electrophysiology. The ventric-
ular mesh had 2,110,030 points and 2,687,615 volumetric elements. 
Finally, myocardial fiber orientations were assigned throughout this 
mesh using a previously validated rules-based approach (42).
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Ee(x) = Ee,0e
–x/į
    (Equation 3)
Optical decay rates (į) for nonmyocardial layers were obtained from 
the available literature, with optical diffusivity values derived from 
absorption and scattering coefficients (ȝa and ȝƍs, respectively) using 
the following formulas:
    (Equation 4)
    (Equation 5)
For the epicardial fat layer, we used parameter values for red light (669 
nm) illumination of subcutaneous adipose tissue (ȝa = 0.0134 mm–1 
and ȝƍs = 1.13 mm–1, D = 0.292 mm, į = 4.66 mm) (60). Relevant mea-
surements of the mammalian pericardium were not found in the liter-
ature; thus, for the pericardium in our model, we used optical param-
eters reported for the human peritoneum (ȝa = 0.0270 mm–1, ȝƍs = 1.83 
mm–1, D = 0.180 mm, į = 2.56 mm) (61, 62).
Protocol for initiation and optogenetic defibrillation of VT. Sus-
tained arrhythmia (≥5 seconds of self-sustained re-entrant activity) 
was initiated by a rapid pacing sequence resembling the clinical pro-
tocol for electrophysiological study in VT patients (59). A train of six 
10-ms-long electrical stimuli (S1) was delivered to the ventricular 
apex at a cycle length of 350 ms. This was followed by a premature 
stimulus (S2, coupling interval = 270 ms), which induced sustained 
VT (Figure 4A, Supplemental Figure 3, and Supplemental Video 1). 
Three unique simulations were conducted with different optogenetic 
configurations: control (no illumination), blue illumination (488 nm), 
and red illumination (669 nm). For the latter 2 cases, light stimulation 
(10 mW/mm2) was applied to the entire epicardial surface for 1 second. 
Light pulse onset time was at t = 4 seconds, approximately 2 seconds 
after the delivery of the S2 stimulus.
Pseudo-ECGs. Extracellular potential from 2 points approximate-
ly 1 cm away from the left and right ventricular surfaces (ĳLV and ĳRV, 
respectively; black dots in Supplemental Figure 3) was calculated using 
an approach we have used in previous studies (63, 64). Pseudo-ECG 
signals (Figure 4, A and B, Supplemental Figure 6B, and Supplemental 
Video 2), analogous to clinical lead I (i.e., left arm minus right arm), 
were obtained by subtraction of ĳRV from ĳLV.
Analysis of diastolic depolarization and Na+ current inactivation. To 
characterize minimal diastolic transmembrane voltage (Vm) values 
within the free ventricular walls (without the septum) during illumi-
nation (Figure 5D), 3D maps of Vm were output at high temporal res-
olution (1-ms time step) for the interval during which stimulation was 
applied (t = 4–5 seconds). Data within the first 100 ms (i.e., t = 4–4.1 
seconds) were excluded from analysis to ensure that these values 
were not biased toward either fast upstrokes associated with the initial 
response to optogenetic stimulation (i.e., directly light-induced action 
potentials) or low preillumination resting potentials. The threshold for 
open states (i.e., k1 and k2 in the Williams et al. model; ref. 15) by 2.2-
fold. This resulted in a half-maximal optogenetic activation level (i.e., 
threshold irradiance to elicit 50% of maximal IChR2) of 0.4 mW/mm2, 
which was consistent with the reported value for CatCh (58). The 
expression for ChR2 photocurrent was:
IChR2 = gChR2(O1 + ȖO2)(VmïEChR2)
    (Equation 1)
where gChR2 was the maximal channel conductance (0.17 mS/cm2), 
Ȗ = 0.1 was the conductance ratio between dark- and light-adapted 
open channel states (O1 and O2, respectively), and EChR2 = 0 mV was 
the ChR2 reversal potential. The ordinary differential equations 
controlling light- and voltage-dependent rates of change in O1, 
O2, and other model state variables can be found in previous pub-
lications (13, 15, 57). At the organ scale, we used a finite element 
approximation of the steady-state photon diffusion equation to 
model light attenuation due to scattering and energy absorption in 
the ventricular myocardium (13, 57). The corresponding partial dif-
ferential equation, which assumes isotropic absorption and homog-
enous scattering, is given by:
'՚ 2Ee(r) – ȝaEe(r) = –w(r)
    (Equation 2)
where Ee and w are, respectively, the distributions of irradiance and 
photon sources at each point r; ՚2 is the Laplace operator; D is the dif-
fusivity of light in cardiac tissue; and ȝa is the light absorption rate. As 
described previously (57), w is set to zero and the equation is solved 
with Dirichlet boundary conditions derived from the placement of 
simulated light sources. We validated this approach in earlier work 
concerned with simulation of optical mapping experiments (20). 
Optical parameters of myocardium were derived from experimental-
ly measured values for cardiac tissue (59) and depended on whether 
the applied illumination was blue (Ȝ = 488 nm, D = 0.18 mm, ȝa = 0.52 
mm–1) or red (Ȝ = 669 nm, D = 0.34 mm, ȝa = 0.10 mm–1). As shown in 
Supplemental Figure 5, this resulted in significantly deeper light pen-
etration for red stimuli (approximate exponential decay rate į = 1.84 
mm) compared with blue stimuli (į = 0.588 mm).
Additional calculations were performed to analyze how optical 
energy requirements for optogenetic defibrillation would be affected 
if red light were applied to the outer surface of the pericardium instead 
of directly to the epicardium. This illumination configuration was 
modeled by assuming the heart was surrounded by a layer of adipose 
tissue (i.e., epicardial fat) and a fibrous sac filled with fluid (i.e., vis-
ceral and parietal pericardial membranes plus pericardial fluid). Both 
layers were assumed to have uniform thickness based on nominal 
measurements from human patients: 1.7 mm for the pericardium (21) 
and 4.1 mm for the epicardial fat layer (22). To quantify how variability 
in the extent of epicardial fat would affect the light energy required 
for optogenetic defibrillation, we considered a range of possible adi-
pose layer thicknesses (0 to 8 mm) and calculated, for each case, the 
applied pericardial Ee necessary to ensure that light with a particular 
Ee,0 value was able to reach the epicardial surface based on the expo-
nential decay approximation:
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90% inactivation of Na+ current (dashed line in Figure 5D) was derived 
by identification of the specific value (Vm = –65.8 mV) for which h' was 
equal to 0.1 in the human ventricular action potential model (43).
Statistics. Because of the exploratory nature of this study, effect siz-
es could not be predicted, and thus prior power analysis to determine 
the sample sizes could not be performed. Randomization and blinding 
for mouse strains were not applicable because the light pulse–induced 
stimulation is disclosing the ChR2 genotype. For statistical compari-
son (Figure 1, B–F, and Figure 2C), we considered only experiments 
in which at least 5 defibrillation attempts could be evaluated for each 
displayed parameter. For each mouse heart, the average termination 
rate for a given illumination parameter was calculated, displayed as 1 
data point in the graphs, and used for subsequent statistical analysis as 
1 biological replicate. Because of the non-normal distribution and the 
unequal variances of average arrhythmia termination rates, the fol-
lowing nonparametric tests were used: the Friedman test to estimate 
the influences of illumination parameters (Figure 1, D–F), the 1-way 
ANOVA Kruskal-Wallis with Dunn’s multiple-comparison post-test for 
comparison between different mouse lines (Figure 1C), and the Wil-
coxon matched pairs t test for comparison between protocols with and 
without illumination in ChR2-expressing hearts (Figure 1B and Figure 
2C). Statistics were calculated with GraphPad Prism (GraphPad Soft-
ware). P values less than 0.05 were considered statistically significant 
and are indicated by *P ≤ 0.05, **P ≤ 0.01, and ***P ≤ 0.001 in the fig-
ures. Data are shown as mean ± SEM unless otherwise indicated.
Study approval. All animal procedures were performed in accor-
dance with the Guide for the Care and Use of Laboratory Animals pub-
 1. Marcus GM, Chan DW, Redberg RF. Recol-
lection of pain due to inappropriate versus 
appropriate implantable cardioverter- 
defibrillator shocks. Pacing Clin Electrophysiol. 
2011;34(3):348–353.
 2. Reynolds MR, et al. The frequency and incremental 
cost of major complications among medicare bene-
ficiaries receiving implantable cardioverter-defibril-
lators. J Am Coll Cardiol. 2006;47(12):2493–2497.
 3. Sohail MR, Henrikson CA, Braid-Forbes MJ, 
Forbes KF, Lerner DJ. Mortality and cost 
associated with cardiovascular implantable 
electronic device infections. Arch Intern Med. 
2011;171(20):1821–1828.
 4. Larsen GK, Evans J, Lambert WE, Chen Y, Raitt 
MH. Shocks burden and increased mortality in 
implantable cardioverter-defibrillator patients. 
Heart Rhythm. 2011;8(12):1881–1886.
 5. Bruegmann T, et al. Optogenetic control of 
heart muscle in vitro and in vivo. Nat Methods. 
2010;7(11):897–900.
 6. Vogt CC, et al. Systemic gene transfer enables 
optogenetic pacing of mouse hearts. Cardiovasc 
Res. 2015;106(2):338–343.
 7. Nussinovitch U, Gepstein L. Optogenetics for in 
vivo cardiac pacing and resynchronization thera-
pies. Nat Biotechnol. 2015;33(7):750–754.
 8. Arrenberg AB, Stainier DY, Baier H, Huisken J. 
Optogenetic control of cardiac function. Science. 
2010;330(6006):971–974.
 9. Zipes DP, Fischer J, King RM, Nicoll A deB, Jolly 
WW. Termination of ventricular fibrillation in 
dogs by depolarizing a critical amount of myocar-
dium. Am J Cardiol. 1975;36(1):37–44.
 10. Burton RA, et al. Optical control of exci-
tation waves in cardiac tissue. Nat Photonics. 
2015;9(12):813–816.
 11. Bingen BO, et al. Light-induced termination of 
spiral wave arrhythmias by optogenetic engi-
neering of atrial cardiomyocytes. Cardiovasc Res. 
2014;104(1):194–205.
 12. Maguire CT, Wakimoto H, Patel VV, Hammer 
PE, Gauvreau K, Berul CI. Implications of ven-
tricular arrhythmia vulnerability during murine 
electrophysiology studies. Physiol Genomics. 
2003;15(1):84–91.
 13. Boyle PM, Williams JC, Ambrosi CM, Entcheva 
E, Trayanova NA. A comprehensive multiscale 
framework for simulating optogenetics in the 
heart. Nat Commun. 2013;4:2370.
 14. Ambrosi CM, Boyle PM, Chen K, Trayanova NA, 
Entcheva E. Optogenetics-enabled assessment 
of viral gene and cell therapy for restoration of 
cardiac excitability. Sci Rep. 2015;5:17350.
 15. Williams JC, et al. Computational optogenetics: 
empirically-derived voltage- and light-sensitive 
channelrhodopsin-2 model. PLoS Comput Biol. 
2013;9(9):e1003220.
 16. Karathanos TV, Bayer JD, Wang D, Boyle PM, 
Trayanova NA. Opsin spectral sensitivity deter-
mines the effectiveness of optogenetic termination 
of ventricular fibrillation in the human heart: a 
simulation study [published online ahead of print 
March 4, 2016]. J Physiol. doi:10.1113/JP271739.
 17. Klapoetke NC, et al. Independent optical exci-
tation of distinct neural populations. Nat Meth-
ods. 2014;11(3):338–346.
 18. Lin JY, Knutsen PM, Muller A, Kleinfeld D, 
Tsien RY. ReaChR: a red-shifted variant of 
channelrhodopsin enables deep transcra-
nial optogenetic excitation. Nat Neurosci. 
2013;16(10):1499–1508.
 19. Kleinlogel S, et al. Ultra light-sensitive and fast neu-
ronal activation with the Ca2+-permeable channel-
rhodopsin CatCh. Nat Neurosci. 2011;14(4):513–518.
 20. Bishop MJ, Rodriguez B, Eason J, Whiteley 
JP, Trayanova N, Gavaghan DJ. Synthesis of 
voltage-sensitive optical signals: application 
to panoramic optical mapping. Biophys J. 
2006;90(8):2938–2945.
 21. Sechtem U, Tscholakoff D, Higgins CB. MRI of 
the normal pericardium. AJR Am J Roentgenol. 
1986;147(2):239–244.
 22. Flüchter S, et al. Volumetric assessment of epi-
cardial adipose tissue with cardiovascular mag-
netic resonance imaging. Obesity (Silver Spring). 
2007;15(4):870–878.
 23. Pezhouman A, et al. Molecular Basis of Hypoka-
lemia-Induced Ventricular Fibrillation. Circula-
tion. 2015;132(16):1528–1537.
 24. Glukhov AV, Flagg TP, Fedorov VV, Efimov IR, 
Nichols CG. Differential K(ATP) channel phar-
macology in intact mouse heart. J Mol Cell Cardi-
ol. 2010;48(1):152–160.
 25. Billman GE. The cardiac sarcolemmal ATP-sen-
sitive potassium channel as a novel target for 
anti-arrhythmic therapy. Pharmacol Ther. 
2008;120(1):54–70.
 26. Zipes DP, Wellens HJ. Sudden cardiac death. Cir-
culation. 1998;98(21):2334–2351.
 27. Arevalo HJ, et al. Arrhythmia risk stratification of 
patients after myocardial infarction using person-
Downloaded from http://www.jci.org on September 15, 2016.   http://dx.doi.org/10.1172/JCI88950
The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
1 1jci.org
alized heart models. Nat Commun. 2016;7:11437.
 28. Kim TI, et al. Injectable, cellular-scale optoelec-
tronics with applications for wireless optogenet-
ics. Science. 2013;340(6129):211–216.
 29. Xu L, et al. 3D multifunctional integumentary 
membranes for spatiotemporal cardiac measure-
ments and stimulation across the entire epicardi-
um. Nat Commun. 2014;5:3329.
 30. Zacchigna S, Zentilin L, Giacca M. Adeno-asso-
ciated virus vectors as therapeutic and investi-
gational tools in the cardiovascular system. Circ 
Res. 2014;114(11):1827–1846.
 31. Werfel S, et al. Rapid and highly efficient induc-
ible cardiac gene knockout in adult mice using 
AAV-mediated expression of Cre recombinase. 
Cardiovasc Res. 2014;104(1):15–23.
 32. Nagel G, Brauner M, Liewald JF, Adeishvili 
N, Bamberg E, Gottschalk A. Light activation 
of channelrhodopsin-2 in excitable cells of 
Caenorhabditis elegans triggers rapid behavioral 
responses. Curr Biol. 2005;15(24):2279–2284.
 33. Prakosa A, et al. Methodology for image-based 
reconstruction of ventricular geometry for 
patient-specific modeling of cardiac electrophysiol-
ogy. Prog Biophys Mol Biol. 2014;115(2–3):226–234.
 34. Deng D, et al. Accuracy of prediction of 
infarct-related arrhythmic circuits from image-
based models reconstructed from low and high 
resolution MRI. Front Physiol. 2015;6:282.
 35. Ashikaga H, et al. Feasibility of image-based simula-
tion to estimate ablation target in human ventricular 
arrhythmia. Heart Rhythm. 2013;10(8):1109–1116.
 36. Arevalo H, Plank G, Helm P, Halperin H, 
Trayanova N. Tachycardia in post-infarction 
hearts: insights from 3D image-based ventricular 
models. PLoS One. 2013;8(7):e68872.
 37. Vadakkumpadan F, et al. Image-based models of 
cardiac structure with applications in arrhyth-
mia and defibrillation studies. J Electrocardiol. 
2009;42(2):157.e1–157.10.
 38. Schmidt A, et al. Infarct tissue heterogeneity by 
magnetic resonance imaging identifies enhanced 
cardiac arrhythmia susceptibility in patients 
with left ventricular dysfunction. Circulation. 
2007;115(15):2006–2014.
 39. Raya SP, Udupa JK. Shape-based interpolation of 
multidimensional objects. IEEE Trans Med Imag-
ing. 1990;9(1):32–42.
 40. McDowell KS, et al. Methodology for 
patient-specific modeling of atrial fibrosis as a 
substrate for atrial fibrillation. J Electrocardiol. 
2012;45(6):640–645.
 41. Prassl AJ, et al. Automatically generated, ana-
tomically accurate meshes for cardiac electro-
physiology problems. IEEE Trans Biomed Eng. 
2009;56(5):1318–1330.
 42. Bayer JD, Blake RC, Plank G, Trayanova NA. A 
novel rule-based algorithm for assigning myo-
cardial fiber orientation to computational heart 
models. Ann Biomed Eng. 2012;40(10):2243–2254.
 43. ten Tusscher KH, Panfilov AV. Alternans 
and spiral breakup in a human ventricular 
tissue model. Am J Physiol Heart Circ Physiol. 
2006;291(3):H1088–H1100.
 44. Pu J, Boyden PA. Alterations of Na+ currents in 
myocytes from epicardial border zone of the 
infarcted heart. A possible ionic mechanism 
for reduced excitability and postrepolarization 
refractoriness. Circ Res. 1997;81(1):110–119.
 45. Dun W, Baba S, Yagi T, Boyden PA. Dynamic 
remodeling of K+ and Ca2+ currents in cells that 
survived in the epicardial border zone of canine 
healed infarcted heart. Am J Physiol Heart Circ 
Physiol. 2004;287(3):H1046–H1054.
 46. Jiang M, Cabo C, Yao J, Boyden PA, Tseng G. 
Delayed rectifier K currents have reduced 
amplitudes and altered kinetics in myocytes 
from infarcted canine ventricle. Cardiovasc Res. 
2000;48(1):34–43.
 47. Decker KF, Rudy Y. Ionic mechanisms of elec-
trophysiological heterogeneity and conduction 
block in the infarct border zone. Am J Physiol 
Heart Circ Physiol. 2010;299(5):H1588–H1597.
 48. Cabo C, Boyden PA. Electrical remodeling of the 
epicardial border zone in the canine infarcted 
heart: a computational analysis. Am J Physiol 
Heart Circ Physiol. 2003;284(1):H372–H384.
 49. Taggart P, et al. Inhomogeneous transmural 
conduction during early ischaemia in patients 
with coronary artery disease. J Mol Cell Cardiol. 
2000;32(4):621–630.
 50. Glukhov AV, et al. Transmural dispersion of 
repolarization in failing and nonfailing human 
ventricle. Circ Res. 2010;106(5):981–991.
 51. Yao JA, Hussain W, Patel P, Peters NS, Boyden PA, 
Wit AL. Remodeling of gap junctional channel 
function in epicardial border zone of healing 
canine infarcts. Circ Res. 2003;92(4):437–443.
 52. Vigmond EJ, Weber dos Santos R, Prassl AJ, Deo 
M, Plank G. Solvers for the cardiac bidomain equa-
tions. Prog Biophys Mol Biol. 2008;96(1–3):3–18.
 53. Vigmond EJ, Hughes M, Plank G, Leon LJ. 
Computational tools for modeling electri-
cal activity in cardiac tissue. J Electrocardiol. 
2003;36(suppl):69–74.
 54. Rodríguez B, Li L, Eason JC, Efimov IR, Trayanova 
NA. Differences between left and right ventricular 
chamber geometry affect cardiac vulnerability to 
electric shocks. Circ Res. 2005;97(2):168–175.
 55. Bishop MJ, Rodriguez B, Qu F, Efimov IR, 
Gavaghan DJ, Trayanova NA. The role of 
photon scattering in optical signal distortion 
during arrhythmia and defibrillation. Biophys J. 
2007;93(10):3714–3726.
 56. Rantner LJ, Arevalo HJ, Constantino JL, Efimov 
IR, Plank G, Trayanova NA. Three-dimension-
al mechanisms of increased vulnerability to 
electric shocks in myocardial infarction: altered 
virtual electrode polarizations and conduction 
delay in the peri-infarct zone. J Physiol (Lond). 
2012;590(18):4537–4551.
 57. Boyle PM, Karathanos TV, Entcheva E, Trayano-
va NA. Computational modeling of cardiac 
optogenetics: Methodology overview & review 
of findings from simulations. Comput Biol Med. 
2015;65:200–208.
 58. Mattis J, et al. Principles for applying optogenetic 
tools derived from direct comparative analysis of 
microbial opsins. Nat Methods. 2012;9(2):159–172.
 59. Wellens HJ, Brugada P, Stevenson WG. Pro-
grammed electrical stimulation of the heart 
in patients with life-threatening ventricular 
arrhythmias: what is the significance of induced 
arrhythmias and what is the correct stimulation 
protocol? Circulation. 1985;72(1):1–7.
 60. Bashkatov AN, Genina ÉA, Kochubey VI, Tuchin 
VV. Optical properties of the subcutaneous adi-
pose tissue in the spectral range 400–2500 nm. 
Opt Spectrosc. 2005;99(5):836–842.
 61. Sandell JL, Zhu TC. A review of in-vivo optical 
properties of human tissues and its impact on 
PDT. J Biophotonics. 2011;4(11–12):773–787.
 62. Wang HW, et al. Broadband reflectance measure-
ments of light penetration, blood oxygenation, 
hemoglobin concentration, and drug concen-
tration in human intraperitoneal tissues before 
and after photodynamic therapy. J Biomed Opt. 
2005;10(1):14004.
 63. Boyle PM, Veenhuyzen GD, Vigmond EJ. Fusion 
during entrainment of orthodromic reciprocating 
tachycardia is enhanced for basal pacing sites but 
diminished when pacing near Purkinje system 
end points. Heart Rhythm. 2013;10(3):444–451.
 64. Boyle PM, Massé S, Nanthakumar K, Vigmond 
EJ. Transmural IK(ATP) heterogeneity as a 
determinant of activation rate gradient during 
early ventricular fibrillation: mechanistic insights 
from rabbit ventricular models. Heart Rhythm. 
2013;10(11):1710–1717.
Downloaded from http://www.jci.org on September 15, 2016.   http://dx.doi.org/10.1172/JCI88950
Supplemental information for
of ventricular arrhythmia in mouse hearts and human simulationsOptogenetic defibrillation
T. Bruegmann, P.M. Boyle, C.C. Vogt, T.V. Karathanos, H.J. Arevalo, B.K. Fleischmann,
N.A. Trayanova, P. Sasse
Legends to l s -3Supplementa  Movie 1 :
Supplementa  Movie 1: Induction of VT via pacing from the apex of the human ventricular model.l
V is rendered on the 3-dimensional surface using the same color scale as in Fig . Normal (left)m ure 4C
and cutaway (right) views are shown. Pink spheres in the left-hand panel indicate locations at which
extracellular potential was recovered to reconstruct pseudo-ECG .the s
Supplementa  Movie 2: Simulation of optogenetic defibrillation in the human ventricles.l
V propagation in the 3-dimensional human ventricular model in cutaway view (top) and correspondingm
pseudo-ECGs (bottom) for three configurations corresponding to Fig Aure 4 , Supplemental Figure 6B
and Figure 4B ure: no stimulus (left), blue light (middle), and red light (right). Same color scale as Fig
4C. Blue and red auras indicate timing of optogenetic stimuli. In pseudo-ECGs, the black boxes indicate
the beginning and end of the interval shown in the movie and the dashed pink link indicates progress
over time.
Supplementa  Movie 3: Dynamics of reentrant wavefront interaction with tissue subjected tol
optogenetic stimulation.
V propagation in the 3-dimensional human ventricular model in a zoomed-in cutaway view for bluem
light (left) and red light (right), corresponding to Fig respectively.Supplemental Figure 6C and ure 5E,
Same color scale as Fig . Blue and red auras indicate timing of optogenetic stimuli. Arrowsure 4C
appear during the movie to highlight reentrant wavefront propagation into the endocardial layer of the
right ventricular free wall (blue light, left) and reentrant wavefront conduction block induced by
optogenetic depolarization (red light, right).
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Supplemental Figure 1: Experimental setup and protocols for optogenetic defibrillation.
( ) Explanted hearts were retrogradely perfused and the ECG was recorded with electrodes placed atA
the right atrium and the ventricular apex (gray). Ventricular arrhythmia induced by electricalwas
stimulation with two silver chloride electrodes (red). Optogenetic defibrillation was tested by illuminating
the anteroseptal epicardium with light stimuli covering 15, 29, or 143 mm areas (blue circles). ( )
2
B
Schematic illustrating the one light pulse protocol: Electrical burst or S1/S2 stimulation was used to
induce ventricular arrhythmia and 3, 5 or 10 s later one 1 s long light pulse (0.4 mW/mm , 143 mm )
2 2
was applied. Optogenetic defibrillation was classified as successful if arrhythmia terminated within 4 s
after start of the illumination (green box). If arrhythmia persisted, the attempt was classified as a failure
and a rescue defibrillation procedure was performed (see Methods). ( ) Schematic illustrating the fourC
light pulse protocol: Arrhythmia was allowed to stabilize for 3-15 s after induction and four identical light
stimuli were applied with 1 to 5 s delay in-between. Optogenetic defibrillation was classified as
successful if arrhythmia terminated between the start of illumination and a predefined period of 2-10 s
after the last light pulse (time period indicated by green box). If arrhythmia persisted, the attempt was
classified as a failure and a rescue defibrillation procedure was performed. For control experiments in
ChR2 expressing hearts without illumination and in hearts without ChR2 expression, spontaneous
arrhythmia termination was assessed in a time window (green boxes in A and B) using the longest
times indicated.
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Supplemental Figure 2: Image-based model of the diseased human ventricles.
D ( )ifferent renderings of the model with surface views of all three tissue types and translucent normalA
myocardium with ( ) or without ( ) the peri-infarct zoneB C .
Supplemental Figure 2
Supplemental 3Figure
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Supplemental 3:Figure Snapshots of V distribution during simulated VT in the diseased humanm
heart model.
( ) WA hole-heart view. Black dots in left-most panel show locations near left and right ventricles where
extracellular potentials were recorded to generate pseudo-ECG signals in Figures 4A,B and
Supplemental Figure 6B  ( ) C z. utaway view with free wall of right ventricle removed for visuali ation.B
Black arrows indicate the direction of the propagating reentrant wavefront that perpetuated VT.
t:        3.6 s
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Supplemental Figure 4
Supplemental Figure 4: ChR2 distribution in the l.ventricular mode
2D slice showing distribution of the ChR2 expressing cardiomyocytes in the normal myocardium and
peri-infarct zone of the human ventricular model.
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Supplemental Figure 5
Supplemental Figure 5: Light attenuation .characteristics in the human ventricular model
3D map showing light attenuation during u redniform illumination of the epicardial surface with light
( nm and light ( nm ). The right ventricular free wall is cut away to facilitate669      , ) blue 488      ,A B
visuali ation. Scale bars for light attenuation factor are logarithmic.z
B
red light attenuation factor
1 10
-1
10
-2
10
-3
10
-4
10
-5
10
-6
blue light attenuation factor
1 10
-1
10
-2
10
-3
10
-4
10
-5
10
-6
A
4
Supplemental Figure 6
A
1 s
0
.5
 m
V
– 85 +35V (mV)m
7
5
 m
V
2
0
0
 p
A
/p
F
1
0
 p
A
/p
F
C
B
t = 4.32 s
t = 4.37 s
t = 4.42 s
0.5 s
INa
ICa,L
1 (Epi)
2 (Mid-myo)
3 (Endo)
Supplemental Figure 6: Optogenetic defibrillation failure using epicardial illumination with blue
light.
( ) Top: V -traces from sites 1-3 in Figure A during epicardial illumination with blue light. Bottom: IonicA m 5
Na and L-type Ca currents underlying V from site 3. ( ) Pseudo-ECG signals for the model
+ 2+
(I ) (I )Na Ca,L m B
configurations with epicardial illumination with blue light. Timing of blue illumination (488 nm, 1 s,
10 mW/mm ) is indicated by blue boxes (A and B). ( ) Zoomed-in snapshots of V distribution during
2
C m
the illumination at the indicated time points (from start of simulation). Snapshots were taken from the
region shown in Figure A top by black rectangl .5 e
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Supplemental Figure 7
Supplemental Figure 7: Requirements for optogenetic defibrillation for illumination from the
pericardium.
( ) Required increase in optical stimulus intensity due to light attenuation in epicardial fat tissueA
(yellow, 4.1 mm) and the pericardium (brown, 1.7 mm) relative to the light intensity reaching the
epicardium (blue x) using global illumination with red light (669 nm). ( ) Required increase in lightB
intensity (red line) for pericardial illumination for different epicardial fat layer thickness values. Dashed
blue line indicates increase in required light intensity due to light attenuation by the 1.7 mm-thick
pericardium only.
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3.3 Epilogue 
This publication was the first report proving the termination of ventricular arrhythmia with 
optogenetic depolarization in intact hearts. The combination of experiments in mouse hearts 
and in silico simulations of an infarcted patient heart revealed a completely new mechanism to 
terminate arrhythmia. We propose that optogenetic stimulation allows transmural 
depolarization to block the excitation wave travelling into the illuminated region. Importantly, 
because illumination and optogenetic depolarization can be sustained for seconds until the 
arrhythmia is terminated, this principle could be much safer compared to brief electrical shocks. 
Furthermore, light generation does not require charging of capacitators for electrical shocks, 
which allows fast repetition of illumination until the arrhythmias have been successfully 
terminated. 
The ability to use optogenetic stimulation to understand to improve current treatment options 
was shown shortly after our publication.166 In this publication, the authors used patterned light 
stimulation and thereby were able to reduce the required light energy compared to global 
illumination. However, this approach was only tested in one type of ventricular tachycardia 
with a specific reentrant wave front. Therefore it remains to be determined how effective this 
patterned light stimulation is for other arrhythmia types or how the light pattern could be 
defined individually in patients. Recently, the feasibility of optogenetic defibrillation was 
demonstrated in rats after AAV-based gene transfer of ChRs.167 The authors suggested 
continuous illumination would prolong the AP and thereby terminated the ventricular 
tachycardia. However, the AP prolongation was only seen in the last AP during the illumination 
and did not happen directly after onset of the illumination. Therefore it can be questioned 
whether the observed AP prolongation is causing or caused by the arrhythmia termination.  
In conclusion, optogenetic defibrillation based on gene transfer of ChRs to cardiomyocytes in 
combination with implantable light emitting devices could become a novel treatment option for 
patients with recurrent ventricular arrhythmia. Because the required gene transfer might put 
patients at risk, the patient cohort would have to be very carefully chosen. Patients suffering 
from electrical storm (generation of at least 3 episodes of ventricular arrhythmia requiring 
electrical defibrillation per day) or patients with many inappropriate shocks would have 
probably the greatest benefit of implantable optogenetic defibrillators. Furthermore optogenetic 
technologies are well suited to investigate the mechanism of defibrillation by electrical shocks 
and might thereby improve current therapeutic strategies. 
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4. Optogenetic stimulation of skeletal muscle 
4.1 Prologue 
Direct stimulation of intact mammalian skeletal muscles with optogenetic methods has not been 
demonstrated but could be very useful to study electrophysiology and excitation-contraction 
coupling in skeletal muscle fibers. Aim of this part was not only to establish direct optogenetic 
stimulation of skeletal muscle but also to carefully characterize the underlying biophysical 
principles and to point out the advantages and limitations of this technology.  
In addition, I explored whether direct optogenetic stimulation of skeletal muscles could be 
suited for therapeutic applications. Because electrical stimulation is restricted in clinics to 
indirect stimulation via motor neurons, optogenetics could provide new treatment options when 
direct stimulation of skeletal muscles is required. Examples for this scenario are peripheral 
nerve injuries and pathologies or diseases affecting the neuromuscular synapses, such as 
amyotrophic lateral sclerosis or myasthenia gravis. In addition, indirect electrical muscle 
stimulation of the nerve is impaired if the nerve fibers within one nerve innervates different 
skeletal muscle groups. In the human larynx, the recurrent laryngeal nerve innervates all 
skeletal muscles involved in opening the vocal cords to allow air passage into the lung during 
breathing and closing the vocal cords for phonation and protection from aspiration. Bilateral 
recurrent nerve paralysis is a severe complication of neck surgery, tumors or central 
neurological diseases168 and results in a fixed paramedian position of the vocal cords and 
eventually life-threatening dyspnea. Current treatment options are the surgical removal of one 
vocal cord, which severely impairs phonation and increases the risk of aspiration or 
alternatively permanent tracheotomy, which leads to high stigmatization, alteration of voice 
and frequent infections. Although electrical stimulation of the posterior cricoarytenoid muscle 
within the larynx has been shown to enable opening of the vocal cords in animals and 
humans,169-175 severe side-effects prevent the routine clinical application. These include 
corrosion or encapsulation of the electrode tip reducing the efficiency of stimulation, discomfort 
due to the activation of sensory nerves, and co-stimulation of antagonistic muscles, which 
requires in some patients the selective silencing of antagonistically acting muscle groups by 
repetitive botulinum toxin injections.171,172 To propose optogenetic stimulation as alternative to 
restore laryngeal functions, I tested the advantage of the high spatial resolution of light for 
specific stimulation of intralaryngeal muscles. 
 
4.2 Original publication 
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mice expressing the light-sensitive channel Channelrhodopsin-2 (ChR2). Largest tetanic
contractions are observed with 5-ms light pulses at 30Hz, resulting in 84% of the maximal
force induced by electrical stimulation. We demonstrate the utility of this approach by
selectively stimulating with a light guide individual intralaryngeal muscles in explanted
larynges from ChR2-transgenic mice, which enables selective opening and closing of the
vocal cords. Furthermore, systemic injection of adeno-associated virus into wild-type mice
provides sufficient ChR2 expression for optogenetic opening of the vocal cords. Thus, direct
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I
n contrast to electrical stimulation, optogenetic methods allow
cell-type-specific stimulation with high spatial and temporal
precision of excitable cells by expressing light-sensitive
proteins such as the light-gated nonselective cation channel
Channelrhodopsin-2 (ChR2)1–3. This technology has been
used to evoke contractions in innervated skeletal muscle by
indirect stimulation of either the secondary motor cortex3 or of
peripheral motor neurons4–6, whereas direct optogenetic
stimulation of skeletal muscle cells was so far shown only in
nematodes7 and in immortalized myotubes in vitro8. These as
well as earlier studies in heart muscle9,10 do not allow to predict
the feasibility and efficacy of direct optogenetic stimulation of
intact mammalian skeletal muscle. This is because maximal force
generation in intact skeletal muscle depends on the recruitment of
electrically isolated muscle fibres, which is potentially challenging
when using direct optogenetic stimulation of skeletal muscle
because of the high concentration of light-absorbing myoglobin.
Furthermore, maximal and sustained force can only be
generated by Ca2þ accumulation during tetanic high-frequency
stimulation, which is in contrast to the non-tetanic heart.
Because of these specific features of skeletal muscle physiology,
we explore herein the biophysical basics of direct optogenetic
stimulation of intact mammalian skeletal muscle. Muscle-specific
expression of ChR2 would allow the spatially controlled and pain-
free stimulation of skeletal muscle, and therefore we test also the
applicability of optogenetic stimulation of individual intralar-
yngeal muscles to illustrate as a proof-of-concept the functional
recovery of paralysed larynges.
Results
Direct optogenetic stimulation of isolated muscle fibres. We
used transgenic mice expressing the ChR2(H134R) mutant in
fusion with enhanced yellow fluorescent protein (EYFP) under
the control of the chicken-b-actin promotor10, which is strongly
active in muscle cells11, and found bright EYFP signals in single
flexor digitorum brevis (FDB) fibres located within the plasma
membrane and in the t-tubulus system (Fig. 1a). Illumination of
isolated single FDB fibres with short light flashes (470 nm, 1ms,
8mWmm 2) induced contractions (Supplementary Movie 1)
proving the direct activation of muscle because isolated single
FDB fibres do not contain neuromuscular synapses.
Light-induced isometric force in intact soleus muscles. To
quantify the potency of optogenetic stimulation in intact skeletal
muscles, isometric force was measured in explanted soleus mus-
cles, which showed EYFP expression (Fig. 1b) in a-actinin-posi-
tive muscle fibres (Fig. 1c). Stimulation with light pulses as short
as 2ms and as low as 0.35mWmm 2 induced contractions and
force gradually increased with higher light intensities (Fig. 1d
left). When using 25-ms-long pulses, force generation saturated at
low light intensities (0.5mWmm 2; Fig. 1d right). Importantly,
with high light intensity (1.4mWmm 2) force could be
increased by prolongation of light pulses from 1 to 50ms, whereas
longer light pulses did not further increase force generation
(Fig. 1e). Comparison of all light intensities and pulse durations
highlighted their interdependence, and longer light pulses led to a
saturation of force at lower light intensities (Fig. 1f). Overall, the
maximal force of light-induced single twitches was 53.2±2.4mN
(n¼ 5) using 100-ms-long light pulses at 0.35mWmm 2.
In order to obtain maximal force in skeletal muscle, sustained
contractions are required. Interestingly, continuous illumination
resulted in non-sustained force generation with an initial peak
followed by a decline to basal levels (Fig. 2a) highlighting the
importance of pulsed stimulation. To determine the most
effective pulsed illumination, we tested a broad range of repetition
rates (10–70Hz) and pulse durations (2–20ms) and analysed the
average force during these stimulations. Using low repetition
rates (10Hz), soleus muscles showed incomplete tetanic contrac-
tions with short relaxations between the light pulses; however,
repetition rates above 30Hz led to complete and uniform tetanic
contractions (Fig. 2a). Overall optical stimulation with 5ms at
30Hz generated the highest average force with 94.3±5.6mN and
the average force per cross-sectional area amounts to
140.1±8.4 kNm 2 (n¼ 6; Fig. 2b). This value was close
(84.0±4.7%) to the maximal force induced by the most effective
electrical stimulation. To analyse the force–frequency relationship
of optical compared with electrical stimulation, we normalized for
each muscle the respective force on optical stimulation with the
maximal force induced by electrical stimulation (Fig. 2c). At low
repetition rates (o30Hz), pulsed illumination was superior to
electrical stimulation in generating force; however, the efficacy of
optical stimulation decreased at repetition rates above 40Hz
(Fig. 2c). In order to determine the mechanism underlying this
effect, we measured the membrane potential of muscle fibres
within the intact soleus muscle using sharp electrodes. We found
that the action potential duration was strongly dependent on the
duration of light pulses (Fig. 3a), and repolarization was delayed
after termination of illumination (Fig. 3b). This can be explained
by the slow off-kinetics (time constant of deactivationB20ms) of
ChR2(H134R)7. Thus, at higher repetition rates, repolarization
did not occur leading to continuous depolarization (Fig. 3c).
Muscle fatigue was not different between optical (5ms, 30Hz,
1.4mWmm 2) and electrical stimulation (20V, 0.1ms, biphasic,
100Hz; Fig. 4). Importantly, isometric force measurements with
soleus muscles from control mice expressing EGFP did not reveal
any light-induced contractions (Fig. 5) confirming the specificity
of optogenetic stimulation.
Optogenetic stimulation of explanted larynges. One clear
advantage of the optogenetic stimulation approach could be the
selective activation of individual agonistic and antagonistic
muscles located in close vicinity. In contrast, electrical stimulation
lacks this spatial precision and indirect stimulation through
motoric nerves is also impossible in case that both muscle groups
are innervated by the same nerve. The mammalian larynx is a
good example because the recurrent laryngeal nerve innervates all
skeletal muscles that control the position of the vocal cords
(Fig. 6a). Contraction of the posterior cricoarytenoid muscle
opens the vocal cords allowing air passage into the lung during
breathing, whereas the other intralaryngeal muscles close the
vocal cords for phonation and protection from aspiration12,13.
We have taken advantage of optogenetic stimulation to
demonstrate selective stimulation of individual intralaryngeal
muscles. For this purpose, an ex vivo preparation of the larynx
was used that reflects the physiological characteristics of a
denervated larynx in vivo including paramedian position and
physiological tension of the vocal cords as well as integrity and
intact biomechanical movement of the intralaryngeal muscles
and the arytenoid cartilage. In explanted larynges from the
ChR2-transgenic mouse line, all muscles displayed bright and
membrane-bound EYFP signals (Fig. 6b). Selective illumination
of the posterior cricoarytenoid muscle was performed with a
light-emitting diode (LED)-coupled small light guide (400-mm
core diameter), and the most efficient stimulation pattern was
determined using 4-s-long stimulations with a broad range of
pulse durations (2–20ms) and repetition rates (10–50Hz).
Illumination with low repetition rates (o20Hz) showed
incomplete tetanic contractions with oscillating movements
(Fig. 6c left), whereas rates above 30Hz led to sustained
opening of the vocal cords (Fig. 6c middle, Supplementary
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Movie 2). Importantly, during continuous illumination we
observed an initial opening with subsequent re-closure (Fig. 6c
right) highlighting the importance of pulsed illumination. For
quantification of vocal cord opening, we calculated the average of
the area between the vocal cords at baseline and during
illumination. Comparison of all tested stimulation patterns
revealed that 10-ms-long light pulses at 40Hz induced the
maximum opening of the vocal cords leading to a change of the
open area from 76±19 to 344±73mm2, which is an increase of
420±131% (n¼ 5; Fig. 6d). In order to take anatomical
variations into account and to compare the effectiveness of
different stimulation patterns, we normalized the respective
openings to the maximal opening (Fig. 6e). Compared with the
maximal opening obtained with 10-ms pulses at 40Hz, we
found that 12 other stimulation patterns had similar efficiency
(nZ3, P40.05, repeated analysis of variance (ANOVA) test
with Bonferroni multiple comparison post test). Among these,
2-ms-long pulses at 40Hz had the lowest duty cycle (8%) and its
use would therefore avoid possible photo damage. To further
prove selectivity of optical stimulation, we moved the light guide
in front of the superior cricoarytenoid muscle, which is
responsible for closure of the vocal cords in mice. Illumination
of this region led to a closing of the vocal cords (Supplementary
Movie 3).
Gene transfer for optogenetic stimulation of wild-type mice.
These proof-of-principle experiments were performed in a
transgenic animal model, whereas for therapeutic purposes
gene transfer of ChR2 into skeletal muscle is required. In order
to demonstrate the feasibility of this approach for optogenetic
control of larynx function in wild-type mice, we have
systemically injected adeno-associated viruses (AAV) expressing
ChR2(H134R) in fusion to mCherry with the capsid of serotype 9
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Figure 1 | Functional expression of ChR2 in skeletal muscle. (a–c) Expression of ChR2-EYFP in skeletal muscles. (a) Single fibres isolated from flexor
digitorum brevis muscles showed bright ChR2-EYFP (green) signals with localization at the cell membrane including the t-tubulus system that surrounds
the a-actinin (magenta) containing z-discs (enlargements in lower panels). (b,c) Bright ChR2-EYFP (green) signals were found in explanted soleus muscles
(b) and were restricted to a-actinin (magenta) positive skeletal muscle cells (c, top). No expression was seen in the tendon identified with haematoxylin
and eosin staining (c, bottom). (d–f) Light-induced single twitches in soleus muscles. (d) Representative examples of single twitches induced by 2- and
25-ms-long light pulses with increasing light intensities. (e) Relationship of pulse duration and maximal twitch force at high light intensity (1.4mWmm 2,
n¼ 5). (f) Overall comparison of the maximum twitch force induced by single light pulses of different durations and intensities (n¼ 5). Error bars, s.e.m.,
nuclear staining in blue, scale bars, 10mm (a), 1mm (b,c).
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms8153 ARTICLE
NATURE COMMUNICATIONS | 6:7153 | DOI: 10.1038/ncomms8153 | www.nature.com/naturecommunications 3
& 2015 Macmillan Publishers Limited. All rights reserved.
because this serotype has been reported to infect skeletal muscles
in mice14. Four weeks after the injection, we could detect
mCherry fluorescence in the posterior cricoarytenoid muscle
(Fig. 7a) and detailed histological analysis revealed that in this
muscle 10.2±3.6% of the fibres (n¼ 3) expressed the ChR2-
mCherry fusion protein. Pulsed illumination (10ms, 40Hz)
applied to the posterior cricoarytenoid muscle of explanted
larynges from the AAV-treated mice led to an opening of the
vocal cords (Fig. 7b and Supplementary Movie 4) with a change
of the open area from 96±14mm2 to a maximum of
227±80mm2, which is an increase of 139±66% (n¼ 4). The
opening was only transient and declined nearly to baseline
during stimulation (Fig. 7b), indicating that AAV-based ChR2
expression must be improved for optogenetic induction of
sustained tetanic contractions.
Discussion
We herein report direct optogenetic stimulation of intact
mammalian skeletal muscle. Even though in skeletal muscle all
of the electrically isolated fibres must be simultaneously
stimulated for maximal force generation, optogenetic stimulation
was found to induce 84% of the maximal force during electrical
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Figure 4 | Fatigue induction during optical and electrical stimulation.
Fatigue development during 350-ms-long tetanic stimulation pattern
(optical, 5ms pulses, 30Hz, 1.4mWmm 2, electrical, 0.1ms, biphasic,
100Hz, 20V) over a time period of 10min. Fatigue values were compared
at each time point using a two-way, paired Student’s t-test resulting in
P values40.05 (n¼ 7).
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stimulation. In contrast to using brief electrical pulses, the ability
to apply longer light pulses allowed the biophysical investigation
of different depolarization patterns on skeletal muscle contrac-
tion, and the high spatial control enabled the selective stimulation
of intralaryngeal muscles.
Using single light pulses of various duration and intensities we
found increasing twitch forces either by applying higher light
intensities or longer pulse durations. This can be explained with
enhanced recruitment of muscle fibres from deeper layers by
using higher intensities and by longer lasting ChR2 photocurrents
both leading to action potential generation in more fibres.
Interestingly, light pulses longer than 50ms had no additional
benefit, indicating that at this pulse duration all fibres are
activated and excitation of the whole muscle is saturated. For
higher and sustained forces, pulsed illumination was required
because continuous illumination induced only a transient
contraction, which highlights the importance of repolarization
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Figure 5 | Optical stimulation in CAG EGFP control mice. Representative
recording (n¼4) of isometric force measurements of soleus muscles from
mice expressing only EGFP during optical stimulation with 5-ms-long pulses
at 30Hz (1.4mWmm 2) and electrical stimulation (10mA, 1ms, 100Hz).
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Figure 6 | Optogenetic opening of the vocal cords. (a) H&E staining of a section through the larynx (top) and schematic drawing displaying the different
muscle groups and cartilages (bottom: P: posterior cricoarytenoid muscle; L, lateral cricoarytenoid muscle, C, cricoid cartilage; VC, vocal cords; T, thyroid
cartilage; Tl, lateral cricothyroid muscle; Tm, medial cricothyroid muscle). (b) Membrane-bound ChR2-EYFP signals (green, enlargement in lower panel)
overlaid with a-actinin staining (magenta) in a consecutive slice. (c) Representative examples of opening of the vocal cords induced by various 4-s-long
illumination patterns. (d) Open area between the vocal cords calculated before and during illumination (10ms light pulses, 35.7mWmm 2, 40Hz
repetition rate, n¼ 5, two-way, paired Student’s t-test, P¼0.0145). (e) Relationship between repetition rate and average open area normalized to maximal
opening for different light pulse durations (35.7mWmm 2, n¼ 3). Error bars, s.e.m., nuclear staining in blue, scale bars, 1mm (a), 500mm (b).
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for proper tetanus induction in skeletal muscle. At low
frequencies (o30Hz), optogenetic stimulation was superior to
electrical stimulation because it allowed longer pulse durations
and hence the prolonged action potentials would result in longer
Ca2þ transients and higher force generation. In contrast, at high
repetition rates (440Hz), the slow off-kinetics of the
ChR2(H134R) variant prevented the repolarization between
pulses. This causes similar to constant illumination, refractoriness
of L-type Ca2þ channels, impaired Ca2þ accumulation and
attenuation of force15. Accordingly, short phases of repolarization
are required for sustained tetanic contractions. Thus, in contrast
to cardiac muscle, where this effect is not present because of the
long action potentials and the inability to generate tetanus, larger
contractile force in skeletal muscles could be generated by high-
rate tetanus induction using ultrafast ChR2 variants with fast off-
kinetics (time constant of deactivationB5ms) such as ChETA16
or Chronos17. Furthermore, light attenuation by blood and
muscle tissue could be decreased using ChR2 variants with red-
shifted excitation spectra18 because of higher light penetrance.
Our experiments also provide proof-of-concept for a transla-
tional approach. Bilateral recurrent nerve paralysis is a severe
complication of various disease processes19 and results in a fixed
paramedian position of the vocal cords and life-threatening
dyspnoea20. Current treatment options are surgical removal of
one vocal cord or permanent tracheotomy; however, these
treatment forms have severe side effects21,22. Alternatively, also
electrical stimulation has been tested; however, this approach is
seriously affected by corrosion or encapsulation of the electrode
tip, discomfort due to the stimulation of sensory nerves and co-
stimulation of antagonist muscles20,23, preventing its clinical use.
Our experiments prove the specific stimulation of small
intralaryngeal muscles to selectively open and close the vocal
cords. Given the anatomic and biomechanical similarities
between larynges from mice and humans24, this approach could
be a potential therapeutic option for patients suffering from
bilateral laryngeal paralysis.
AAVs would be a very promising tool for the expression of
ChR2 because several clinical trials have already proven their
efficacy and safety for therapeutic gene transfer into skeletal
muscles in humans25–27. The transduction rate in the larynx
could be enhanced by either using catheter-based intravascular
injection into laryngeal vessels, or local intramuscular injection of
AAV. Selective expression of ChR2 in skeletal muscle cells would
enable pain-free optogenetic stimulation, and selective targeting
of ChR2 to the most fatigue-resistant slow twitch muscle fibres
could be used to reduce muscle fatigue. Moreover, direct
optogenetic stimulation of muscle could be also applied in
diseases that affect peripheral nerves or synaptic transmission,
such as amyotrophic lateral sclerosis or myasthenia gravis in
which the previously reported indirect optogenetic stimulation
through peripheral nerves4–6 would fail.
In summary, we demonstrate the feasibility and the biophysical
basics of direct optogenetic stimulation in intact mammalian
skeletal muscle. Its high efficacy as well as the advantage of site-
specific and time-controlled excitation of skeletal muscle makes
this an ideal approach to explore basic principles in muscle
physiology and to develop this further towards translation.
Methods
Transgenic mouse model. Experiments were performed using the previously
reported10 transgenic mouse line expressing the ChR2 (H134R) variant under the
control of the chicken-b-actin (CAG) promoter; in total, eight male mice (ages 2–8
months, median 2.5 months) and six females (ages 5–8 months, median 4.8
months) were used. Transgenic mice (three female mice, 7 months old) expressing
EGFP under control of the CAG promoter10 served as controls in Fig. 5. Both lines
were backcrossed Z10 generations on a CD1 genetic background. Animal
experiments conformed with the Guide for the Care and Use of Laboratory
Animals published by the US National Institutes of Health (eighth edition, revised
2011). For the harvesting of tissue, mice were killed by cervical dislocation and
dissection of skeletal muscle was performed in ice-cold bicarbonate Tyrode
solution containing (in mM) 118 NaCl, 3.4 KCl, 0.8 MgSO4, 1.2 KH2PO4,
11.1 Glucose, 25 NaHCO3 and 2.5 CaCl2 gassed with 95% O2 and 5% CO2 at room
temperature. Preparation of FDB muscles was performed in ice-cold Tyrode
solution containing (in mM) 140 NaCl, 5.4 KCl, 1.8 CaCl2, 2 MgCl2, 10 glucose and
10 Hepes (pH 7.4, adjusted with NaOH) and preparation of explanted larynges
was performed in ice-cold DPBS (Gibco, Life technologies).
Single FDB fibre preparation. To obtain single FDB fibres, FDB muscles were
explanted and dissociated with 2mgml 1 collagenase B (Roche) in Tyrode
solution for 1 h at 37 C. Single FDB fibres were plated on glass coverslips coated
with 100 mgml 1 Laminin (Sigma-Aldrich) and incubated for 2–3 h at room
temperature in Tyrode solution. Illumination (470 nm) was performed on an
Axiovert 200 microscope (Zeiss) through a  20 Fluar objective (numerical
aperture: 0.75, Zeiss) with a temperature-controlled LED module (Omicron,
LEDMOD LAB 470 nm, Omicron Laserage). Videos were recorded at 60 fps with a
CMOS camera (Basler A602f) and the Fire-I Application 5.51 software (UniBrain).
Isometric force measurements. Soleus muscles were explanted and incubated in
Bicarbonate Tyrode solution containing (in mM) 118 NaCl, 3.4 KCl, 0.8 MgSO4,
1.2 KH2PO4, 11.1 Glucose, 25 NaHCO3 and 2.5 CaCl2 gassed with 95% O2 and
5% CO2 at room temperature. To measure isometric force, soleus muscles were
mounted between a force transducer (KG 2, Scientific Instruments) and a fixed
hook. For illumination, a temperature-controlled LED module (Omicron,
LEDMOD LAB 470 nm, Omicron Laserage) was coupled to a plastic optical fibre
(2mm diameter, numerical aperture (NA)¼ 0.5) and directed into the window of
the muscle recording chamber resulting in the illumination of the whole muscle.
Light intensity was calibrated by measuring the power (PM100 powermeter with
S130A sensor, Thorlabs) at the site of muscle placement within the recording
chamber.
Control of LED and recording of force were performed with a Powerlab 8/30
recording system and the Chart 7.1 software (AD Instruments). Electrical stimuli
were generated by a stimulator (Stim7, Scientific Instruments or stimulator 2100,
AM Systems) connected to the force transducer and the hook. Soleus muscles were
pre-stretched until single light stimuli (10ms, 1.4mWmm 2) evoked maximal
force generation. This optimal muscle length was multiplied by 0.85 to calculate the
optimal fibre length as previously reported28. To confirm the viability of the
skeletal muscle before the optical activation, soleus muscles were activated with a
maximal electrical tetanus stimulation (20V, 0.1ms biphasic, 100Hz, 2 s) and, only
if this muscle yielded a maximum force generation above 70mN, it was used for
further experiments. Light-induced single twitches were evoked with at least 10-s
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Figure 7 | Functional ChR2 expression in the larynx after AAV-based gene transfer. (a) mCherry expression (magenta) in a-actinin (white)-positive
fibres of the posterior cricoarytenoid muscle (autofluorescence in green, enlargements in lower panels). (b) Representative example of the transient
opening of the vocal cords during 2-s-long pulsed illumination (10ms, 40Hz, 35.7mWmm 2). Nuclear staining in blue, scale bar, 200mm.
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intervals between stimulations. Tetanic contractions induced by optical and
electrical stimulation were 2 s long with an interval of 3min between stimulations.
Directly after force recording, tendons were removed and soleus muscles were
blotted on tissue paper to remove the excess fluid and weighed. For quantification,
maximal force was analysed for single twitch contractions and the average force
during tetanic contractions was normalized to cross-sectional area that was
calculated as weight/(optimal fibre length density (1.06mgmm 3) as previously
reported28. For the analysis of the force–frequency relationship (Fig. 2c), force was
normalized to the maximal force induced by electrical stimulation (20V, 1ms,
biphasic) to account for variation between muscles. To analyse fatigue induction,
350-ms-long tetanic optical or electrical stimulation pattern were applied every
3.7 s over a total period of 10min similarly as reported before using the best optical
(5ms, 30Hz, 1.4mWmm 2) and electrical (100Hz, 20 V, 0.1ms, biphasic)
stimulation pattern29.
Recording of membrane potential from intact skeletal muscles. For intracel-
lular recording of membrane potential, soleus muscles were mounted, over-
stretched to 110–130% of optimal length and 25mM 2,3-Butanedione monoxime
(Sigma) was added to the bicarbonate Tyrode solution in order to alleviate con-
tractions. Sharp electrodes (filled with 3M KCl, 50–150MO) were impaled into the
soleus muscle using a piezomanipulator (PM10, Maerzhaeuser Wetzlar) and
membrane potential was recorded with a bridge amplifier (BA-03X, npi electronic),
the Powerlab 8/30 recording system and the Chart 7.1 software (AD Instruments).
Only cells with a resting membrane potential more negative than  50mV and
action potentials with overshoot above 0mV were included into the analysis.
Action potential duration was determined by measuring the time from the peak to
repolarization to  35mV.
Analysis of laryngeal function ex vivo. Explanted larynges were placed in
bicarbonate Tyrode solution (for composition see above) gassed with 95% O2 and
5% CO2. For optical stimulation a light guide (Ø 400 mm, NA 0.48) was coupled to
a 470-nm LED (M470F1, Thorlabs), controlled by a Powerlab 8/30 recording
system and the Chart 7.1 software (AD Instruments) and placed directly in front of
the posterior cricoarytenoid muscles or the superior cricoarytenoid muscles. Light
intensity was calibrated at the tip of the light guide, and this might be therefore an
overestimate. For visualization explanted larynges were illuminated from the top
with white light from a cold-light source (Olympus KL2500LCD) and videos
were recorded through a macroscope (MVX10, Olympus) equipped with a  1
Objective (MVPLAPO1x, NA 0.25, Olympus) and a 542±27-nm bandpass filter
(F37-542, AHF Analysetechnik) to block the stimulation light. For each stimulation
pattern, a single video file was recorded at 15 or 30 f.p.s. with a CMOS camera
(Basler A602f) and the Fire-I Application 5.51 software (UniBrain). Videos of the
same larynx were merged, and only videos in which the whole area between the
vocal cords was darker than the surrounding tissue of the larynges could be used
for the automatic analysis. Brightness adjustments and converting into binary
images by threshold analysis was performed with the Virtual Dub video processing
software. This conversion resulted in a video in which the area between the vocal
cords was black and the surrounding tissue turned white. A custom-made, Lab-
view-based area analysis software detected and calculated the black area between
the vocal cords over time. Calibration of pixel size was used to determine the
absolute areas (in mm2). Traces of the open area between the vocal cords over time
were further analysed using the Chart 7.1 software (AD Instruments). The average
open area was analysed by determining the integral of the open area and was
normalized to the maximal average opening of each muscle in order to take
anatomical variations into account.
AAV injection and analysis of efficacy. Injection of AAV was approved by the
local ethics review board. The AAV9-CAG-hChR2(H134R)-mCherry virus con-
sisting of the AAV9 virus capsid and AAV2 virus DNA were ordered from the
Penn Vector Core from the University of Pennsylvania. Ten-week-old female mice
(CD1, Charles River) were anaesthetized by inhalation of 1.5% isoflurane and
O2/N2O (50%/50%). Overall, 2 1011 genome copies of AAV diluted in 100 ml PBS
were injected slowly (B10 s) through a 1-ml syringe (Insuline Syringe U-40, BD)
connected to a sterile 33-gauge needle (200 mm diameter, Nanopass 33, Terumo)
into the left jugular vein. Bleeding was carefully stopped using surgical swabs
trapped in forceps, and the lesion was closed with a suture (Prolene C-1 13mm
3/8c, Ethicon). Four weeks later, larynges were explanted and tested with the same
set-up as described above using 2 or 4 s long, pulsed stimulation with a pulse
duration of 10ms and a repetition rate of 40Hz, and the open area between
the vocal cords was manually determined in individual frames using the area
measurement tool of the ImageJ software (NIH).
Histology and immunofluorescence staining. Single FDB fibres, soleus muscles
and explanted larynges were fixated with 4% paraformaldehyde (PFA). Cryopre-
served muscles and larynges were sectioned with a cryotome (Cryostat CM3050 S,
Leica) into 10-mm-thick slices. Slices of larynges were stained with haematoxylin
and eosin (H&E) according to the standard protocols and consecutive slices were
used for immunohistochemical stainings. All sections were permeabilized with
0.2% Triton X in PBS, and immunohistochemical stainings were performed in 5%
donkey serum for 2 h at room temperature with a primary antibody to the a-
actinin protein (1:400, Sigma-Aldrich). Cy3- or Cy5-conjugated secondary anti-
bodies (1:400, Jackson ImmunoResearch) were diluted in Hoechst 33342 for
nuclear staining. Pictures of native soleus muscles and laryngeal H&E sections were
acquired with a stereomicroscope (AxioZoom.V16, Zeiss), and fluorescence pic-
tures of laryngeal slices, soleus muscles and single FDB fibre were acquired with an
inverted fluorescence microscope (Axio Imager, Zeiss). To analyse the percentage
of muscle fibres with ChR2-mCherry expression after systemic AAV injection,
fluorescence images were acquired with a mCherry filter set (F46-008, AHF
Analysentechnik) and overlaid with native autofluorescence signals acquired with a
Cy2 filter set and a-actinin staining using the Cy3 channel. The number of
mCherry-positive muscle fibres was counted and normalized to all muscle fibres
identified by a-actinin staining.
Statistics. Statistical data are shown as mean±s.e.m. For comparison of different
stimulation patterns, repeated ANOVA tests were performed using Dunnett’s
multiple comparison tests for isometric force measurements with continuous light
stimulation as control (Fig. 2b) or Bonferroni multiple comparison test for opening
of the vocal cords. For comparison of the average open area between vocal cords
before and during illumination (Fig. 6d) a one-way, paired Student’s t-test and for
comparison of fatigue induction by optical and electrical stimulation (Fig. 4) a two-
way paired Student’s t-test was chosen. The n values in the legends indicate the
number of independent experiments (muscles or larynges), and a Po0.05 was
considered statistically significant.
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4.3 Epilogue 
Light induced depolarization of ChR2 expressing skeletal muscles allows completely new 
experiments for the investigation of skeletal muscle physiology because it enables for the first 
time uniform control over the membrane potential in intact skeletal fibers and muscles. 
Importantly, this is neither possible with electrical intracellular stimulation due to loss-of-
voltage control nor with extracellular electrical field stimulation as explained above. Focused 
illumination on different parts of the cell membrane could be used to search for hot spots of 
excitability which are predicted at the site of the neuromuscular endplate or to quantify the 
different propagation kinetics of the electrical excitation at the sarcolemma surface and within 
the t-tubular membrane.138 Global illumination enables uniform depolarization of the whole 
myofiber and the level and duration can be fine-grain controlled by the light intensity and pulse 
duration. This allows novel investigations of excitation-contraction-coupling mechanism in 
greater detail than using nerval or electrical stimulation. In addition, optogenetic proteins can 
be specifically expressed only in skeletal muscles and even specifically in fast or slow myofiber 
types using appropriate promotors. This would allow investigations of retrograde feedback and 
forward-loops between skeletal muscle and motor neuron activity176 as well as mimicking the 
physiological fiber recruitment and lower fatigue development if the slower muscle fiber 
become selectively activated. 
Interestingly, our approach for direct optogenetic stimulation of skeletal muscles was recently 
confirmed and extended to in vivo stimulation in transgenic mice.177 Furthermore, the authors 
used repetitive optogenetic stimulation over several days to attenuate atrophy generation in 
denervated fibers which supports the clinical prospects of direct optogenetic stimulation of 
skeletal muscles. 
5. Conclusion
In my thesis, I focused on describing the feasibility and mechanistic advantages of optogenetic 
stimulation of striated muscle and it is based on two ground breaking publications in the 
respective fields. In the first publication, I was able to prove that the sustained optogenetic 
depolarization can be used to terminate ventricular arrhythmia in intact mouse hearts. 
Excitingly, I suggest that optogenetic defibrillation terminates arrhythmia by a completely 
different mechanism compared to electrical shocks which could add to the efficacy and thus 
safety in future clinical applications. Furthermore optogenetic depolarization will enable to 
better understand the mechanism underlying the termination of tachyarrhythmia by electrical 
shocks.  
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In the second publication, I showed the feasibility and characterized the biophysical principles 
of direct optogenetic stimulation of intact skeletal muscles. This proved distinct advantages 
over electrical stimulation. Importantly, optogenetic stimulation enables the precise spatial 
control of the membrane potential in the whole elongated myofiber. The fine grain control over 
duration and depolarization will allow investigation of the excitation-contraction coupling 
machinery in much greater detail and even in intact muscles. Furthermore, the feasibility to 
directly stimulate skeletal muscle with considerably low energy will raise hope for therapeutic 
applications in neuromuscular diseases which cannot be treated with electrical stimulation so 
far. 
Therefore optogenetic stimulation of striated muscles is a unique tool to address open questions 
in basic research due to its unprecedented spatial precision and ability to control the membrane 
potential of cells in intact tissues. Importantly, the possibility to perform cell-specific 
stimulation allows a tantalizing outlook for therapeutic applications in heart and skeletal muscle 
pathologies.  
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Katrin Zimmermann, Martin Breitbach, Britta Engelbrecht, Tobias Brügmann, Michael 
Hesse, Armin Welz, Philipp Sasse, Daniela Wenzel, Christian Plank, Bernhard Gleich, 
Michael Hölzel, Wilhelm Bloch, Alexander Pfeifer, Bernd K. Fleischmann & Wilhelm Roell. 
Biomaterials 2017; 10.1016/j.biomaterials.2017.11.012 
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Tobias van Bremen T, Thorsten Send, Philipp Sasse* & Tobias Bruegmann* 
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Hendrik Lapp,* Tobias Bruegmann,* Daneila Malan, Stephanie Friedrichs, Carsten Kilgus, 
Alexandra Heidsieck & Philipp Sasse 
Scientific  Reports 2017;7:9629. 
4. Synchronization of excitable cardiac cultures of different origin
Nadezda N. Agladze, Oleh V. Halaidych, Valeriya A. Tsvelaya, Tobias Bruegmann, Carsten 
Kilgus, Philipp Sasse & Konstantine I. Agladze 2017.
Biomaterials Science 2017; 10.1039/c7bm00171a. 
5. Optogenetic defibrillation terminates ventricular arrhythmia in mouse hearts and
human simulations 
Tobias Bruegmann*, Patrick M. Boyle*, Christoph C. Vogt, Thomas V. Karathanos, 
Hermenegild J. Arevalo, Bernd K. Fleischmann, Natalya A. Trayanova & Philipp Sasse 
Journal of Clinical Investigation 2016; 126:3894-3904 
6. Optogenetic control of contractile function in skeletal muscle
Tobias Bruegmann, Tobias van Bremen, Christoph C. Vogt, Thorsten Send, Bernd K. 
Fleischmann & Philipp Sasse 
Nature Communications 2015; 10.1038/ncomms8153 
7. Systemic gene transfer enables optogenetic pacing of mouse hearts
Christoph C. Vogt*, Tobias Bruegmann*, Daniela Malan, Annika Ottersbach,
Wilhelm Roell, Bernd K. Fleischmann & Philipp Sasse  
Cardiovascular Research 2015; 106:338-343
8. Optogenetic activation of Gq-signalling modulates pacemaker activity of
cardiomyocytes
Thomas Beiert, Tobias Bruegmann & Philipp Sasse  
Cardiovascular Research 2014; 102:507-516. 
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9. Optogenetic cardiac pacemakers: Science or fiction?
Tobias Bruegmann & Philipp Sasse 
Trends in Cardiovascular Medicine 2014; S1050-1738(14)00194-7 
10. Optogenetic control of heart muscle in vitro and in vivo
Tobias Bruegmann, Daniela Malan, Michael Hesse, Thomas Beiert, Christoph J. Fuegemann, 
Bernd K. Fleischmann & Philipp Sasse 
Nature Methods 2010; 7: 897-900 
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.2 Talks and Poster presentations 
Talks:
Optogenetische Cardioversion/Defibrillation und optogenetischer Larynxschrittmacher: 
Warum, wie und was gibt es noch zu tun? 
Innovationsforum Optogenetik, Hannover 2017 
Optogenetic stimulation of muscle cells: Shining new light on (patho-) physiology and 
illuminating new treatment options 
Fortbildungsveranstaltung der pädiatrische Kardiologie, Intensivmedizin und EMAH der 
MHH Hannover, 2017 
Optogenetic termination of atrial fibrillation in the mouse heart 
Annual Conference of the German Genetics Society, Bochum 2017 
Optogenetic stimulation for the heart: Shining new light on (patho-) physiology and 
illuminating new treatment options 
Seminar des Internationalen Graduiertenkollegs 1816, Göttingen 2017  
Optogenetics in muscle cells: shining light on excitation of skeletal and cardiac muscle for 
laryngeal pacemaking, cardioversion and defibrillation 
Veterinärmedizinisches Kolloquium der Universität Leipzig, 2017 
Optogenetic stimulation of muscle cells: Shining new light on physiology and illuminating 
new treatment options 
Award Lecture of the Du Bois-Reymond Prize, 96. Jahrestagung der Deutschen 
Physiologischen Gesellschaft 2017, Greifswald 
Optogenetic termination of atrial fibrillation in the mouse heart 
96. Jahrestagung der Deutschen Physiologischen Gesellschaft 2017, Greifswald
Optogenetic termination of atrial fibrillation in the mouse heart 
Gordon Research Seminar on “Cardiac Arrhythmia Mechanisms” 2017, Ventura, USA 
Optogenetic control of laryngeal muscles
Neurolaryngology workshop for experts, Jena 2016 
Optogenetic termination of atrial fibrillation in the mouse heart 
40th  Official Meeting of the European Working Group on Cardiac Cellular Electrophysiology 
2016, Glasgow, Schottland 
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Understanding and treating cardiac arrhythmia - from mice and goat to man 
(zusammen mit Ulrich Schotten, Maastricht University),  
95. Jahrestagung der Deutschen Physiologischen Gesellschaft 2016, Lübeck
Optogenetics in muscle cells: shining light on excitation and intracellular signaling of smooth, 
skeletal and cardiac muscle. 
1st Workshop Brazil Germany Cardiac regeneration and electrophysiology 2014, Rio de 
Janeiro, Brasilien 
Optogenetic defibrillation of ventricular tachycardia in the murine heart 
4. Symposium der Jungen Physiologen, Leipzig
Optogenetics in cells and whole hearts 
Cardiostim 2014, Nizza, Frankreich 
Optogenetics in muscle cells: A new tool for light-induced depolarization in muscle cells 
5th Basel muscle symposium on skeletal muscle 2013, Basel, Schweiz 
Optogenetische Kontrolle über Gefäßkontraktion - Einsatz von Kanalrhodopsin 2 in glatter 
Muskulatur der Gefäße 
1. Symposium der Jungen Physiologen 2011, Leipzig
Channelrhodopsin expression in cardiomyocytes: A new tool for light-induced depolarization 
with high spatio-temporal resolution in vitro and in vivo 
40. Jahrestagung der DGTHG 2011, Stuttgart
Lichtinduzierte Depolarisation von Channelrhodopsin 2 exprimierenden Kardiomyozyten  
BONFORsymposium 2010, Bonn 
Channelrhodopsin expression in cardiomyocytes: A new tool for light-induced depolarization 
with high spatio-temporal resolution in vitro and in vivo
Joint Meeting of the Scandinavian and German Physiological Societies 2010, Kopenhagen, 
Dänemark 
Poster presentations: 
Frequency-dependent multi-well cardiotoxicity screening enabled by optogenetic stimulation 
41st Meeting of the European Working Group on Cardiac Cellular Electrophysiology im 
Rahmen des EHRA Europace 2017, Wien, Österreich 
Optogenetic termination of atrial fibrillation in the mouse heart 
Gordon Research Conference on “Cardiac Arrhythmia Mechanisms” 2017 
Ventura, USA 
Terminating ventricular arrhythmia by optogenetic hyperpolarisation 
ESC Congress 2016, Rom, Italien  
Optogenetic defibrillation of ventricular tachycardia in the murine heart 
Gordon Research Seminar and Conference: “Cardiac Arrhythmia Mechanisms” 2015, Lucca, 
Italien 
Optogenetic control of skeletal muscle: a new method to treat laryngeal paralysis 
93. Jahrestagung der Deutschen Physiologischen Gesellschaft 2014, Mainz
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Optogenetic stimulation of skeletal muscles 
Biophysical Society 58th Annual Meeting 2014, San Francisco, USA 
Optogenetic control of vascular tone with high temporal resolution
Biophysical Society 57th Annual Meeting 2013, Philadelphia, USA 
Optogenetics in cardiovascular research: a new tool for light-induced depolarization of 
cardiomyocytes and vascular smooth muscle cells in vitro and in vivo
ESC Congress 2011, Paris, Frankreich  
Optogenetic control of vascular contraction 
90. Jahrestagung der Deutschen Physiologischen Gesellschaft 2011,  Regensburg
Light-induced depolarization to stimulate cardiomyocytes with high spatio-temporal 
resolution and to modulate their differentiation in vitro
Biophysical Society 54th Annual Meeting 2010, San Francisco, USA 
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